0001886799 false --12-31 Q2 0001886799 2023-01-01 2023-06-30 0001886799 2023-08-16 0001886799 2023-06-30 0001886799 2022-12-31 0001886799 us-gaap:RelatedPartyMember 2023-06-30 0001886799 us-gaap:RelatedPartyMember 2022-12-31 0001886799 2023-04-01 2023-06-30 0001886799 2022-04-01 2022-06-30 0001886799 2022-01-01 2022-06-30 0001886799 us-gaap:CommonStockMember 2023-03-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001886799 us-gaap:RetainedEarningsMember 2023-03-31 0001886799 2023-03-31 0001886799 us-gaap:CommonStockMember 2022-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001886799 us-gaap:RetainedEarningsMember 2022-12-31 0001886799 us-gaap:CommonStockMember 2022-03-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001886799 us-gaap:RetainedEarningsMember 2022-03-31 0001886799 2022-03-31 0001886799 us-gaap:CommonStockMember 2021-12-31 0001886799 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001886799 us-gaap:RetainedEarningsMember 2021-12-31 0001886799 2021-12-31 0001886799 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001886799 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001886799 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001886799 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001886799 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001886799 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001886799 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001886799 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001886799 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001886799 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001886799 us-gaap:CommonStockMember 2023-06-30 0001886799 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001886799 us-gaap:RetainedEarningsMember 2023-06-30 0001886799 us-gaap:CommonStockMember 2022-06-30 0001886799 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001886799 us-gaap:RetainedEarningsMember 2022-06-30 0001886799 2022-06-30 0001886799 us-gaap:PrivatePlacementMember srt:MaximumMember 2023-02-01 2023-02-01 0001886799 us-gaap:PrivatePlacementMember 2023-02-01 0001886799 us-gaap:CommonStockMember BGXX:AccreditedInvestorAndExistingStockholderMember 2023-05-20 2023-05-21 0001886799 us-gaap:CommonStockMember BGXX:AccreditedInvestorAndExistingStockholderMember 2023-05-21 0001886799 BGXX:AccreditedInvestorAndExistingStockholderMember us-gaap:PrivatePlacementMember 2023-05-21 0001886799 us-gaap:BuildingMember 2023-06-30 0001886799 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001886799 srt:MinimumMember 2023-06-30 0001886799 srt:MaximumMember 2023-06-30 0001886799 BGXX:AlterolaBiotechIncMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember BGXX:SellersMember 2022-10-02 2022-10-03 0001886799 BGXX:SellersMember 2023-06-30 0001886799 BGXX:SellersMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember BGXX:SellersMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember 2022-10-02 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember 2023-06-30 0001886799 2023-01-01 2023-03-31 0001886799 BGXX:VotingAgreementMember 2022-10-02 2022-10-03 0001886799 BGXX:VotingAgreementMember BGXX:SellersMember 2022-10-02 2022-10-03 0001886799 BGXX:AlterolaBiotechIncMember 2023-03-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-12-31 0001886799 BGXX:AlterolaBiotechIncMember 2023-01-01 2023-03-31 0001886799 BGXX:AlterolaBiotechIncMember 2022-01-01 2022-03-31 0001886799 BGXX:VenloStyleGreenHouseMember BGXX:NMMember 2023-06-30 0001886799 us-gaap:ConstructionInProgressMember 2023-06-30 0001886799 us-gaap:ConstructionInProgressMember 2022-12-31 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2020-10-05 2020-10-05 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2020-10-05 2021-06-30 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2021-07-01 2021-12-31 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2022-01-01 2022-01-01 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementOneMember 2022-01-01 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2020-10-21 2020-10-21 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2021-01-01 2021-12-31 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2022-01-01 2022-01-01 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2022-01-01 0001886799 BGXX:GrantGreenhouseGrowersIncMember BGXX:RealEstateOptionAgreementTwoMember 2021-07-01 2021-12-31 0001886799 us-gaap:EquipmentMember 2022-12-31 0001886799 us-gaap:EquipmentMember 2022-01-01 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:UnsecuredLineOfCreditMember us-gaap:PrimeRateMember BGXX:LDSCapitalLLCMember 2022-06-05 0001886799 BGXX:AmendedUnsecuredLineOfCreditMember 2022-11-14 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2023-01-01 2023-06-30 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-01-01 2022-12-31 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2023-06-30 0001886799 BGXX:UnsecuredLineOfCreditMember BGXX:LDSCapitalLLCMember 2022-12-31 0001886799 2023-02-01 2023-02-01 0001886799 2023-02-06 2023-02-06 0001886799 2023-02-06 0001886799 2023-03-14 2023-03-14 0001886799 BGXX:OneAccreditedInvestorMember 2023-02-01 2023-02-28 0001886799 BGXX:OneAccreditedInvestorMember 2023-02-28 0001886799 us-gaap:CommonStockMember BGXX:BoardMemberMember 2023-02-01 2023-02-28 0001886799 us-gaap:CommonStockMember BGXX:BoardMemberMember 2023-02-28 0001886799 2023-02-01 2023-02-28 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2023-03-01 2023-03-31 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2023-03-31 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-03-01 2023-03-31 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-03-31 0001886799 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2023-05-01 2023-05-31 0001886799 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2023-05-31 0001886799 us-gaap:PrivatePlacementMember 2023-05-01 2023-05-31 0001886799 us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-06-01 2023-06-30 0001886799 us-gaap:CommonStockMember BGXX:ExecutiveChairmanMember 2023-06-30 0001886799 us-gaap:PrivatePlacementMember 2022-09-07 2022-09-07 0001886799 us-gaap:PrivatePlacementMember 2022-09-07 0001886799 BGXX:SecuritiesPurchaseAgreementMember 2022-09-07 0001886799 us-gaap:PrivatePlacementMember 2022-09-07 2022-09-12 0001886799 2022-09-07 2022-09-12 0001886799 2022-09-12 0001886799 BGXX:SecuritiesPurchaseAgreementMember 2023-05-21 0001886799 us-gaap:PrivatePlacementMember 2023-05-22 2023-05-24 0001886799 2023-05-22 2023-05-24 0001886799 2022-09-06 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-01 2023-05-31 0001886799 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2023-05-31 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2022-01-01 2022-01-31 0001886799 us-gaap:CommonStockMember BGXX:OneAccreditedInvestorMember 2022-01-31 0001886799 us-gaap:CommonStockMember srt:ChiefFinancialOfficerMember 2022-04-01 2022-04-30 0001886799 us-gaap:CommonStockMember srt:ChiefFinancialOfficerMember 2022-04-30 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:SixConsultantsMember 2022-04-01 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:SixConsultantsMember 2022-04-30 0001886799 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember BGXX:SixConsultantsMember 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:DirectorsMember 2022-01-01 2022-01-31 0001886799 us-gaap:CommonStockMember BGXX:DirectorsMember 2022-04-01 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:DirectorsMember 2022-01-31 0001886799 us-gaap:CommonStockMember BGXX:DirectorsMember 2022-04-30 0001886799 us-gaap:CommonStockMember BGXX:TwoAccreditedInvestorMember 2022-05-01 2022-05-31 0001886799 us-gaap:CommonStockMember BGXX:TwoAccreditedInvestorMember 2022-05-31 0001886799 us-gaap:CommonStockMember BGXX:ConsultantsMember 2019-06-01 2019-06-30 0001886799 us-gaap:CommonStockMember BGXX:ConsultantsMember 2022-06-01 2022-06-30 0001886799 us-gaap:CommonStockMember BGXX:ConsultantsMember 2019-06-30 0001886799 us-gaap:CommonStockMember BGXX:ConsultantsMember 2022-06-30 0001886799 BGXX:ExecutiveChairmanMember 2023-01-01 2023-06-30 0001886799 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-06-30 0001886799 BGXX:ExecutiveChairmanMember us-gaap:AccruedLiabilitiesMember 2023-06-30 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:AccruedLiabilitiesMember 2023-06-30 0001886799 srt:ChiefExecutiveOfficerMember us-gaap:AccountsPayableMember 2023-06-30 0001886799 srt:ChiefFinancialOfficerMember us-gaap:AccountsPayableMember 2023-06-30 0001886799 BGXX:BoardMemberMember 2023-06-30 0001886799 us-gaap:SubsequentEventMember BGXX:ConsultantMember 2023-07-31 2023-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:acre xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___ to ___

 

Commission File Number: 001-41395

 

BRIGHT GREEN CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   83-4600841

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1033 George Hanosh Boulevard

Grants, NM

  87020
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (833) 658-1799

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   BGXX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
       
Non-accelerated filer Smaller reporting company
       
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of August 16, 2023, there were 179,620,858 shares of the registrant’s common stock outstanding and nil shares of the registrant’s preferred shares outstanding.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
PART I. FINANCIAL INFORMATION  
     
Item 1 Financial Statements (unaudited) 1
  Condensed Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022 2
  Condensed Statements of Operations and Comprehensive Loss (unaudited) for the three and six months ended June 30, 2023 and June 30, 2022 3
  Condensed Statements of Changes in Stockholders’ Equity (unaudited) for the three and six months ended June 30, 2023 and June 30, 2022 4
  Condensed Statements of Cash Flows (unaudited) for the six months ended June 30, 2023 and June 30, 2022 5
  Notes to the Condensed Financial Statements (unaudited) 6
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 24
Item 3 Quantitative and Qualitative Disclosures About Market Risk 26
Item 4 Controls and Procedures 27
   
PART II. OTHER INFORMATION  
     
Item 1 Legal Proceedings 28
Item 1A Risk Factors 28
Item 2 Unregistered Sales of Equity Securities 28
Item 3 Defaults Upon Senior Securities 28
Item 4 Mine Safety Disclosures 28
Item 5 Other Information 28
Item 6 Exhibits 29
   
Signatures 30

 

i
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements.” All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “continues,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” “would” or “should” or, in each case, their negative or other variations or comparable terminology. They appear in a number of places throughout this Quarterly Report on Form 10-Q, and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our results of operations, financial condition, liquidity, prospects, growth, strategies, future acquisitions and the industry in which we operate.

 

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We believe that these risks and uncertainties include, but are not limited to, those described in the “Risk Factors” section of this Quarterly Report on Form 10-Q.

 

These factors should not be construed as exhaustive and should be read with the other cautionary statements in this Quarterly Report on Form 10-Q.

 

Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and industry developments may differ materially from statements made in or suggested by the forward-looking statements contained in this Quarterly Report on Form 10-Q. The matters summarized under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this Quarterly Report on Form 10-Q could cause our actual results to differ significantly from those contained in our forward-looking statements. In addition, even if our results of operations, financial condition and liquidity, and industry developments are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, those results or developments may not be indicative of results or developments in subsequent periods.

 

In light of these risks and uncertainties, we caution you not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make in this Quarterly Report on Form 10-Q speaks only as of the date of such statement, and we undertake no obligation to update any forward-looking statement or to publicly announce the results of any revision to any of those statements to reflect future events or developments, except as required by applicable law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data.

 

ii
 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) 

 

 

Condensed Financial Statements (Unaudited)

 

BRIGHT GREEN CORPORATION

 

June 30, 2023 and 2022

 

(Expressed in United States Dollars)

 

BRIGHT GREEN CORPORATION
 
For the Three Months and Six Months Ended June 30, 2023 and 2022 (Unaudited)

 

Table of Contents

 

Condensed Balance Sheets 2
Condensed Statements of Operations and Comprehensive Loss 3
Condensed Statements of Changes in Stockholders’ Equity 4
Condensed Statements of Cash Flows 5
Notes to the Condensed Financial Statements 6 - 23

 

1
 

 

BRIGHT GREEN CORPORATION
Condensed Balance Sheets
As at June 30, 2023 and December 31, 2022
(Expressed in United States Dollars)

 

   June 30, 2023   December 31, 2022 
   (Unaudited)     
ASSETS          
Current assets          
Cash  $507,445   $414,574 
Prepaid expenses and other assets   182,117    77,847 
Total current assets   689,562    492,421 
           
Deposits (Notes 5 and 9)   1,109,643    1,157,587 
Equity method investment (Note 6)   3,986,019    3,990,960 
Property, plant, and equipment (Note 7)   19,100,647    17,146,325 
Intangible assets (Note 8)   1,000    1,000 
           
Total assets  $24,886,871   $22,788,293 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable (Note 12)  $5,408,503   $5,033,831 
Accrued liabilities (Note 12)   945,911    447,325 
Due to others (Note 6)   1,650,000    1,650,000 
Due to related party (Note 10)   -    392,194 
Total current liabilities   8,004,414    7,523,350 
           
Long-term liabilities          
Related party line of credit note (Notes 10 and 12)   3,561,657    3,686,107 
Total long-term liabilities   3,561,657    3,686,107 
           
Total liabilities   11,566,071    11,209,457 
           
STOCKHOLDERS’ EQUITY          
Common stock; $.0001 par value; 500,000,000 stock authorized; 179,483,020 and 173,304,800 stock issued and outstanding at June 30, 2023 and December 31, 2022, respectively (Note 11)   17,948    17,329 
Additional paid-in capital (Note 11)   52,984,109    45,637,328 
Accumulated deficit   (39,681,257)   (34,075,821)
Total stockholders’ equity   13,320,800    11,578,836 
           
Total liabilities and stockholders’ equity  $24,886,871   $22,788,293 
           
Going Concern (Note 2)          
Commitments (Note 9)          
Contingencies (Note 13)          
Subsequent events (Note 14)          

 

The accompanying notes are an integral part of the condensed financial statements.

 

2
 

 

BRIGHT GREEN CORPORATION
Condensed Statements of Operations and Comprehensive Loss (Unaudited)
For the Three Months and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

   June 30, 2023   June 30, 2022   June 30, 2023   June 30, 2022 
   Three Months Ended   Six Months Ended 
   June 30, 2023   June 30, 2022   June 30, 2023   June 30, 2022 
                 
Revenue  $-   $-   $-   $- 
                     
Expenses                    
                     
General and administrative expenses   2,827,296    18,986,431    5,282,378    19,520,971 
Depreciation   159,210    194,662    316,751    386,468 
Total operating expenses   2,986,506    19,181,093    5,599,129    19,907,439 
                     
Loss from operations  $(2,986,506)  $(19,181,093)  $(5,599,129)  $(19,907,439)
                     
Other expense                    
                     
Foreign currency transaction loss   724    -    1,366    - 
Total other expense   724    -    1,366    - 
                     
Loss before income taxes and equity in net losses of affiliate  $(2,987,230)  $(19,181,093)  $(5,600,495)  $(19,907,439)
                     
Income tax expense   -    -    -    - 
                     
Loss before equity in net losses of affiliate  $(2,987,230)  $(19,181,093)  $(5,600,495)  $(19,907,439)
                     
Equity in net losses of affiliate (Note 6)   (4,941)   -    (4,941)   - 
                     
Net loss and comprehensive loss  $(2,992,171)  $(19,181,093)  $(5,605,436)  $(19,907,439)
                     
Weighted average common shares outstanding - basic and diluted   176,240,466    158,901,214    174,851,640    158,231,923 
                     
Net loss per common share - basic and diluted  $(0.02)  $(0.12)  $(0.03)  $(0.13)

 

The accompanying notes are an integral part of the condensed financial statements.

 

3
 

 

BRIGHT GREEN CORPORATION
Condensed Statements of Changes in Stockholders’ Equity (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

   Shares   Amount   capital   deficit   equity 
   Three Months and Six Months Ended June 30, 2023 
           Additional       Total 
   Common Stock   paid-in   Accumulated   stockholders’ 
   Shares   Amount   capital   deficit   equity 
                     
Balance at March 31, 2023   174,423,810   $17,441   $48,431,116   $(36,689,086)  $11,759,471 
                          
Common stock and warrants issued for cash in a private placement, net of issuance costs of $395,250 (Note 11)   3,684,210    368    3,104,382    -    3,104,750 
Common stock issued for services (Note 11)   1,375,000    139    1,448,611    -    1,448,750 
Net loss   -    -    -    (2,992,171)   (2,992,171)
                          
Balance at June 30, 2023   179,483,020   $17,948   $52,984,109   $(39,681,257)  $13,320,800 
                          
Balance at December 31, 2022 (Audited)   173,304,800   $17,329   $45,637,328   $(34,075,821)  $11,578,836 
                          
Common stock and warrants issued for cash in a private placement, net of issuance costs of $395,250 (Note 11)   3,684,210    368    3,104,382    -    3,104,750 
Warrants exercised for cash (Note 11)   200,000    20    209,980    -    210,000 
Common stock issued for a cashless conversion from related party LOC for EB-5 program (Note 11)   22,005    2    879,998    -    880,000 
Common stock issued for cash for EB-5 program (Note 11)   22,005    2    879,998    -    880,000 
Common stock issued for services (Note 11)   2,250,000    227    2,272,423    -    2,272,650 
Net loss   -    -    -    (5,605,436)   (5,605,436)
                          
Balance at June 30, 2023   179,483,020   $17,948   $52,984,109   $(39,681,257)  $13,320,800 

 

   Shares   Amount   capital   deficit   equity 
   Three Months and Six Months Ended June 30, 2022 
           Additional       Total 
   Common Stock   paid-in   Accumulated   stockholders’ 
   Shares   Amount   capital   deficit   equity 
                     
Balance at March 31, 2022   157,557,000   $15,755   $14,668,388   $(7,140,090)  $7,544,053 
                          
Common stock issued for cash (Note 11)   300,000    30    2,999,970    -    3,000,000 
Common stock issued for services (Note 11)   2,074,490    207    14,595,713    -    14,595,920 
Common stock cancelled that was issued for services (Note 11)   (113,000)   (11)   (17,441)   -    (17,452)
Net loss   -    -    -    (19,181,093)   (19,181,093)
                          
Balance at June 30, 2022   159,818,490   $15,981   $32,246,630   $(26,321,183)  $5,941,428 
                          
Balance at December 31, 2021 (Audited)   157,544,500   $15,754   $14,618,389   $(6,413,744)  $8,220,399 
                          
Common stock issued for cash (Note 11)   312,500    31    3,049,969    -    3,050,000 
Common stock issued for services (Note 11)   2,074,490    207    14,595,713    -    14,595,920 
Common stock cancelled that was issued for services (Note 11)   (113,000)   (11)   (17,441)   -    (17,452)
Net loss   -    -    -    (19,907,439)   (19,907,439)
                          
Balance at June 30, 2022   159,818,490   $15,981   $32,246,630   $(26,321,183)  $5,941,428 

 

The accompanying notes are an integral part of the condensed financial statements.

 

4
 

 

BRIGHT GREEN CORPORATION
Condensed Statements of Cash Flows (Unaudited)
For the Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

   June 30, 2023   June 30, 2022 
   Six Months Ended 
   June 30, 2023   June 30, 2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES          
           
Net loss  $(5,605,436)  $(19,907,439)
           
Adjustments to reconcile net cash used in operating activities:          
Equity in net losses of affiliate   4,941    - 
Depreciation   316,751    386,468 
Stock-based compensation   2,272,650    14,578,468 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   (104,270)   62,700 
Accounts payable   374,672    1,252,950 
Accrued liabilities   498,586    87,580 
Accrued interest   163,356    - 
Net cash used in operating activities   (2,078,750)   (3,539,273)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
           
Deposits   47,944    - 
Purchase of property, plant, and equipment   (2,271,073)   (2,614,319)
Net cash used in investing activities   (2,223,129)   (2,614,319)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
           
Proceeds from related party line of credit   200,000    2,000,000 
Proceeds from issuance of common stock   880,000    3,050,000 
Proceeds from issuance of common stock and warrants, issued in private placement, net of issuance costs   3,104,750    - 
Proceeds from warrants exercised   210,000    - 
Net cash provided by financing activities   4,394,750    5,050,000 
           
NET INCREASE (DECREASE) IN CASH   92,871    (1,103,592)
CASH, BEGINNING OF PERIOD   414,574    1,282,565 
CASH, END OF PERIOD  $507,445   $178,973 
           
CASH PAID FOR          
Interest  $-   $- 
Taxes  $-   $- 
           
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES          
Transfer from due to related party to related party LOC  $392,194   $- 
Related party LOC in exchange for common stock for EB-5 program  $(880,000)  $- 

 

The accompanying notes are an integral part of the condensed financial statements.

 

5
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

1. Description of Business and Organization

 

Bright Green Corporation (the “Company,” “our,” “us,” “we,” or “Bright Green”) was incorporated on April 16, 2019, under the Delaware General Corporation Law. The Company’s principal executive office is located in Grants, New Mexico. The Company holds the land, greenhouse and patents required in the growth, production, and research of medicinal plants.

 

On March 29, 2022, the Company filed a registration statement pursuant to the Securities Act of 1933, as amended (the “Securities Act”) on Form S-1 with the Securities and Exchange Commission (“SEC”), which was declared effective May 13, 2022, (as amended, the “Registration Statement”), in connection with the direct listing of the Company’s common stock with the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”).

 

On May 17, 2022, the Company’s common stock commenced trading on Nasdaq under the symbol “BGXX.”

 

On February 1, 2023, the Company initiated a private placement offering of our common stock, only to accredited or qualified institutional investors, in reliance upon Rule 506, Regulation D promulgated under the Securities Act, pursuant to the U.S. government’s EB-5 immigrant investor program. Under our EB-5 Program, we may issue up to an aggregate of 12,609,152 shares of common stock at $39.99 per share.

 

On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company for the sale by the Company of (i) 3,684,210 shares of the Company’s common stock, par value $0.0001 per share, and (ii) warrants to purchase up to an aggregate of 3,684,210 shares of the Company’s common stock, in a private placement offering. The combined purchase price of one share and accompanying warrant was $0.95. The shares and the warrants were sold and issued without registration under the Securities Act of 1933, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 of Regulation D promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

 

The Company is a start-up company at June 30, 2023 and has no revenue.

 

2. Going Concern and Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cashflows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations.

 

The financial information contained in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which the Company filed on April 17, 2023. The results of operations for the six months ended June 30, 2023 are not necessarily indicative of the results for the year ending December 31, 2023.

 

6
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

2. Going Concern and Basis of Presentation (continued)

 

For the six months ended June 30, 2023 and 2022, the Company had no revenues from product sales and incurred a net loss of $5,605,436 and $19,907,439, respectively. Net cash used in operations for the six months ended June 30, 2023, and 2022 was $2,078,750 and $3,539,273, respectively. The Company has incurred recurring losses from operations, and as of June 30, 2023, had an accumulated deficit of $39,681,257 (December 31, 2022 – $34,075,821) and had a negative working capital of $7,314,852 (December 31, 2022 – $7,030,929).

 

The Company is in its initial stages of building facilities to grow, research, and distribute medical plants. The Company has historically financed its operations through the sale of equity securities and debt financing. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the condensed financial statements were authorized to be issued. Therefore, the Company’s continued existence depends on its ability to continue executing its operating plan and obtaining additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan.

 

During the six months ended June 30, 2023, the Company raised $3,104,750 through the issuance of common stock and accompanying warrants to purchase shares of common stock from the Company’s private placement offering in May 2023, $880,000 through common stock issuances from the Company’s EB-5 Program, and $210,000 through the exercise of warrants. The Company also has drawn $200,000 from the Company’s $15,000,000 line of credit from a related party. The Company also had two cashless conversions, the related party line of credit was used to pay in full the related party loan balance of $392,194, and the related party line of credit was paid down $880,000 in exchange for 22,005 shares of the Company’s common stock valued at $39.99 per share according to the Company’s EB-5 Program, leaving available $11.4 million to draw from that credit facility (Note 10). However, there is substantial doubt about the Company’s ability to continue as a going concern due to the necessity to generate positive cash flows from operations and/or obtain additional financing. There is no assurance that the Company will be able to generate positive cash flows from operations or obtain additional financing on terms acceptable to the Company, if at all.

 

In addition, the Company’s current and future operations are subject to various risks and uncertainties, including but not limited to general economic conditions, competition, and regulatory matters. Accordingly, the Company’s operation plan is predicated on various assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue raising additional financing, and the state of the general economic environment in which the Company operates.

 

7
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

2. Going Concern and Basis of Presentation (continued)

 

These risks and uncertainties may have a material adverse effect on the Company’s financial condition and operating results. Management has taken actions to address the Company’s liquidity needs, including managing expenses, developing pathways to revenue, and pursuing additional financing, such as the EB-5 Capital Program announced on February 1, 2023. However, there can be no assurance that such actions will be sufficient to enable the Company to continue as a going concern. There can be no assurance that these assumptions will prove accurate in all material respects or that the Company will be able to successfully execute its operating plan.

 

The condensed financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In addition, the Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be canceled with minimal fees, noncancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.

 

The Company’s ability to continue as a going concern is dependent upon the outcome of the matters described above. The condensed financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

This disclosure is intended to inform users of the condensed financial statements about the Company’s current financial condition and its ability to continue as a going concern. The Company will continue to monitor its liquidity position and take appropriate actions as necessary to address any potential going concern issues.

 

3. Summary of Significant Accounting Policies

 

  A. Basis of Measurement

 

The condensed financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.

 

  B. Property, Plant, and Equipment

 

Property, plant, and equipment is stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant, and equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

 

8
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  B. Property, Plant, and Equipment (continued)

 

  Building and improvement - declining balance method 10 year life
  Furniture and fixtures - straight-line method 3 year life

 

Construction in progress is not depreciated until the asset is placed in service.

 

  C. Long-lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

 

  D. Intangible Assets

 

The Company’s intangible assets consist of certain licenses (Note 8) which will be amortized over the term of each license. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

 

  E. Fair Value of Financial Instruments

 

In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

 

  Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

 

9
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  E. Fair Value of Financial Instruments (continued)

 

  Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and
     
  Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of June 30, 2023 and December 31, 2022 due to their short-term nature.

 

   F. Investments Under the Equity Method

 

When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. In addition, the Company may recognize its share of an investee’s earnings based on an estimated amount for the investee’s earnings when the investee’s financial information is not sufficiently timely for the Company’s reporting period.

 

Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.

 

Derivative Financial Instruments

 

The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the condensed statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s condensed balance sheets.

 

10
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  G. Advertising Costs

 

Advertising costs are charged to operations when incurred. Advertising costs totaled $20,333 and $35,857 for the six months ended June 30, 2023 and 2022, respectively.

 

  H. Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed its methodology for estimating the valuation allowance. A change in valuation allowance affects earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

  I. Basic and Diluted Earnings (Loss) per share

 

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.

 

11
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  J. Segment Reporting

 

ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s condensed financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at June 30, 2023 and 2022 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.

 

  K. Use of Estimates

 

The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, going concern assessment, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

  L. Stock-based Compensation

 

The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the condensed statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

 

12
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  L. Stock-based Compensation (continued)

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.

 

  M. Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each condensed balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed statements of operations and comprehensive loss.

 

  N. Standards, Amendments, and Interpretations Adopted

 

  1) Modification of Equity-Classified Written Call Options

 

In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (here-after referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment

 

13
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  N. Standards, Amendments, and Interpretations Adopted (continued)

 

  1) Modification of Equity-Classified Written Call Options (continued)

 

to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods within those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.

 

  2) Leases

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.

 

The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.

 

A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of June 30, 2023, the Company has one month to month lease, whereas the new standard does not apply.

 

  3) Fair Value Measurement

 

In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).

 

14
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

4. Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $271,268 and $187,821 in excess of the FDIC insured limit at June 30, 2023 and December 31, 2022, respectively.

 

5. Deposits

 

As of December 31, 2022, deposits were comprised of one down payment for a construction of equipment contract for which the Company had not yet taken title and one down payment for a construction contract for which the work had not started. As of June 30, 2023, the Company has still not taken title of the equipment and the construction contract was completed (Note 9).

 

6. Equity Method Investment in Alterola

 

On October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity, Equipped4 Holdings Limited, a United Kingdom entity, TPR Global Limited, a United Kingdom entity (each, a “Seller” and collectively, the “Sellers”) and Alterola Biotech Inc., a Nevada corporation (“Alterola”) providing for the purchase by Bright Green of shares of Common Stock of Alterola from the Sellers (the “Transferred Shares”).

 

The Secondary SPA provides that, as of the date thereof, the authorized shares of Alterola consist of 2,000,000,000 shares of common stock, $0.001 par value, of which 807,047,948 shares are issued and outstanding. The Sellers Transferred Shares consisted of, in aggregate, 201,761,982 shares of Common Stock, which were sold to Bright Green for a purchase price of $3,999,999, pursuant to the payment schedule set forth in the Secondary SPA. As of June 30, 2023 and December 31, 2022, the Company has a liability to the Sellers of $1,650,000, which is in default at June 30, 2023. The Company is currently negotiating a new agreement with the Sellers to resolve the issue. The liability is not interest bearing and not secured. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Transferred Shares, pursuant to a loan agreement.

 

The Sellers held 67% of Alterola’s total outstanding shares prior to the closing of the Secondary SPA. As a result of this transaction, Bright Green obtained ownership or voting power of approximately 25% of the total outstanding shares of Alterola.

 

15
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

6. Equity Method Investment in Alterola (continued)

 

Concurrently with the signing of the Secondary SPA, Bright Green and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agree to vote in favor of the adoption of an agreement to effect Bright Green’s acquisition of Alterola or the Alterola’s merger into Bright Green or a subsidiary of Bright Green, as the case may be, pursuant to additional terms set forth in the Voting Agreement. The agreement will terminate upon the earlier of eight months from the date of the agreement or written notice by Bright Green.

 

Concurrently with the execution of the Voting Agreement, each Stockholder agrees to deliver to Bright Green an Irrevocable Proxy (“Proxy”). The Proxy only applies to the matter of voting upon the aspects regarding Bright Green’s purchase of the remaining 75% of Alterola’s common stock. It does not apply to the Stockholder’s voting on any other business matters pertaining to Alterola. As stated in the Proxy, Bright Green ensures the terms of the deal for the complete acquisition of Alterola are of no less value than as specified in the Press Release dated August 30, 2022, where the valuation of Alterola was determined to be $50 million. It is anticipated that the balance of the enterprise value will be paid as 20% of each shareholding in cash and the remaining 80% in Bright Green stock.

 

The Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Alterola common shares at cost, including transaction costs incurred to obtain the equity method investment of $339,115 in equity method investment in the condensed balance sheets.

 

Due to an inability to timely obtain the June 30, 2023’s financial information for Alterola, the following table provides summarized balance sheet information available for Alterola as of March 31, 2023 and December 31, 2022:

 

   March 31, 2023   December 31, 2022 
         
Current assets  $237,184   $192,011 
Non-current assets   12,139,779    12,018,147 
Current Liabilities   2,127,103    1,822,696 
Non-current liabilities   154,313    151,255 
Equity  $10,095,547   $10,236,207 

 

Due to an inability to timely obtain the June 30, 2023’s financial information for Alterola, the following table provides summarized income statement information available for Alterola for the three months ended March 31, 2023 and 2022:

 

   March 31, 2023   March 31, 2022 
   Three Months Ended 
   March 31, 2023   March 31, 2022 
         
Total revenues  $-   $- 
Net loss  $19,766   $3,257,819 

 

16
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

6. Equity Method Investment in Alterola (continued)

 

The Company’s ownership percentage of 25% of Alterola allows the Company to have significant influence over the operations and decision-making at Alterola. Accordingly, the investment is accounted for as an equity method investment. Since the June 30, 2023 financial results of Alterola will not be available until the third quarter of 2023, the Company will recognize its share of net loss from its investment in Alterola on a three-month lag and will adjust for any known significant changes from the lag period to the reporting date of the Company. The Company’s share of net loss from its investment in Alterola was $4,941 for the three months ended March 31, 2023. As at June 30, 2023, there were no significant changes to disclose.

 

On April 4, 2023, the Company announced its intention to acquire the remaining issued and outstanding common stock of Alterola. However, as of June 30, 2023, the Company is currently negotiating a new agreement with the Sellers.

 

Voting Agreement

 

The Voting Agreement was initially measured at fair value utilizing the Black-Scholes-option-pricing model based on the following assumptions: dividend rate of 0.0%, risk free rate of 4.0%, term of 0.5 years, volatility of 66.0%, the stock price of $26.4 million, inclusive of a Control Premium of 65% valued at $10.4 million, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999.

 

As of December 31, 2022, the value of the option was impaired to $nil to reflect the likelihood that the option would be exercised according to the terms set forth. At June 30, 2023, the option has expired.

 

7. Property, Plant, and Equipment

 

The Company owns an expansive 22-acre modern Dutch “Venlo style” glass greenhouse situated on 70 acres in Grants, New Mexico. It is being retrofitted for growing, processing and distribution of medicinal plants, including Marijuana, for medical researchers licensed by the Drug Enforcement Administration.

 

Property, plant, and equipment at June 30, 2023 and December 31, 2022, consisted of the following:

 

   June 30, 2023   December 31, 2022 
Furniture and fixtures  $88,690   $88,690 
Land   260,000    260,000 
Construction in progress   13,007,342    10,736,269 
Building and improvement   8,883,851    8,883,851 
Property, plant, and equipment gross   22,239,883    19,968,810 
Accumulated depreciation   (3,139,236)   (2,822,485)
Net property, plant, and equipment  $19,100,647   $17,146,325 

 

17
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

7. Property, Plant, and Equipment (continued)

 

The amount of interest costs capitalized and included in construction in progress totaled $269,473 and $106,117 as at June 30, 2023 and December 31, 2022, respectively (Note 10).

 

Real Estate Options

 

In 2020, the Company entered into a merger agreement with Grants Greenhouse Growers, Inc. and acquired the following two land options:

 

  - A Real Estate Option Agreement dated October 5, 2020, and expiring on December 31, 2021, for $1,500 monthly payments up until June 30, 2021, and $1,750 monthly payments from July 1, 2021 to December 31, 2021, with a one-year extension starting on January 1, 2022 for $2,000 monthly payments, with the option to purchase 330 acres for $5,000 per acre.
     
  - A Real Estate Option Agreement dated October 21, 2020, and expiring on December 31, 2021, for $1,000 monthly payments, with a one-year extension starting on January 1, 2022 for $1,500 monthly payments, with the option to purchase 175 acres for $5,000 per acre.

 

As of December 31, 2022, the Company notified the two land owners of the Company’s intention to exercise the two Real Estate Option Agreements. The Company is in the process of negotiating final terms of the two acquisitions. As of June 30, 2023, the acquisitions have not been completed.

 

8. Intangible Assets

 

Intangible assets at June 30, 2023 and December 31, 2022, consisted of the following:

 

   June 30, 2023   December 31, 2022 
Licenses  $1,000   $1,000 
Accumulated amortization   -    - 
Net intangible assets  $1,000   $1,000 

 

9. Commitments

 

In 2022, the Company entered a contract to purchase equipment for $2,219,285. The Company made a deposit totaling $1,109,643 as of December 31, 2022. The remaining balance of $1,109,642 is due upon delivery. The Company also entered into and paid in full a construction contract for $47,944 as of December 31, 2022. The construction was completed in March 2023, and the contract was fulfilled (Note 5).

 

18
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

10. Related Party Line of Credit Note

 

On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Board, entered into an unsecured line of credit in the form of a note (the “June Note”). The Note provides that the Company may borrow up to $5.0 million, including an initial loan of $3.0 million, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Prior to the June Note Maturity Date, the Company may borrow up to an additional $2.0 million under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds from Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of 2% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JPMorgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the Maturity Date, additional penalty interest will accrue on such Loan in the amount of 2% per annum. The Company amended the line of credit on November 14, 2022, to increase the capacity by $10 million. On January 31, 2023, LDS Capital LLC assigned the note to its sole member, Lynn Stockwell, who is a member of the Board and majority shareholder of the Company.

 

As of June 30, 2023, the Lender has funded the Company $5,783,250 (December 31, 2022  ̶  $5,191,057), with the Company paying back $2,491,066 (December 31, 2022  ̶  $1,611,067) of those funds. As of June 30, 2023, there was accrued interest of $269,473 (December 31, 2022  ̶  $106,117). The funds have been used for the construction in progress and interest expense of $269,473 (December 31, 2022  ̶  $106,117) has been capitalized (Note 7).

 

On February 1, 2023, through a cashless conversion, the related party line of credit note was used to pay in full the related party loan balance of $392,194.

 

On February 6, 2023, through a cashless conversion, the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment for 22,005 shares of the Company’s common stock valued at $39.99 per share pursuant to the Company’s EB-5 Program (Note 11).

 

On March 14, 2023, the Company drew an additional $200,000 on the related party line of credit note.

 

11. Stockholders’ Equity

 

The Company has authorized 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock. As of June 30, 2023, and December 31, 2022, there were 179,483,020 and 173,304,800, respectively, of common shares issued and outstanding. The Company has not issued any preferred shares to date.

 

19
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

11. Stockholders’ Equity (continued)

 

During the six months ended June 30, 2023, the Company issued the following:

 

  - 200,000 warrants exercised in exchange for 200,000 shares of common stock issued for cash at $1.05 per share, to one accredited investor in February 2023;
     
  - 22,005 shares of common stock issued at $39.99 per share, to a member of the Board in February 2023, through a cashless conversion; the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment, pursuant to the Company’s EB-5 Program (Note 10);
     
  - 22,005 shares of common stock issued at $39.99 per share, to one accredited investor in March 2023, pursuant to the Company’s EB-5 Program;
     
  - 875,000 shares of common stock for services rendered, at a fair value of $0.9416 per share, to the Company’s Executive Chairman, in March 2023 (Note 12);
     
  - 500,000 shares of common stock for services rendered, at a fair value of $1.13 per share, to the Company’s Chief Executive Officer, in May 2023 (Note 12);
     
  - 3,684,210 shares of common stock and warrants to purchase up to an aggregate of 3,684,210 shares of common stock, at a combined purchase price of $0.95 per share and accompanying warrant, in a private placement offering, in May 2023 (the “May 2023 Private Placement”); and
     
  - 875,000 shares of common stock for services rendered, at a fair value of $1.01 per share, to the Company’s Executive Chairman, in June 2023 (Note 12).

 

Private Placement Offerings

 

September 2022 Private Placement

 

On September 7, 2022, the Company entered into a Securities Purchase Agreement with investors for the sale by the Company of 9,523,810 shares of common stock and warrants to purchase up to an aggregate of 9,523,810 shares of common stock. The combined purchase price of one share and the accompanying warrant (“September 2022 Warrants”) was $1.05. Subject to certain ownership limitations, the September 2022 Warrants are exercisable immediately after issuance at an exercise price equal to $1.05 per share of Common Stock, subject to adjustments as provided under the terms of the September 2022 Warrants. The September 2022 Warrants have a term of five years from the date of issuance. The September 2022 Private Placement closed on September 12, 2022. The Company received gross proceeds of approximately $10 million before deducting transaction-related fees and expenses payable by the Company. As of June 30, 2023, 200,000 of the September 2022 Warrants have been redeemed for $210,000.

 

20
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

11. Stockholders’ Equity (continued)

 

In connection with the September 2023 Private Placement, the Company entered into a Registration Rights Agreement with the investors. The Company’s registration statement on Form S-1 to register the securities issued in the September 2022 Private Placement went effective on September 21, 2022.

 

Transaction costs incurred related to the September 2022 Private Placement include the following: (i) placement agent fees of $800,000, (ii) legal expenses of $55,617, and (iii) escrow agent expenses of $7,650.

 

May 2023 Private Placement

 

On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company. The combined purchase price of one share and the accompanying warrant (“May 2023 Warrants”) was $0.95. Subject to certain ownership limitations, the May 2023 Warrants are exercisable immediately after issuance at an exercise price equal to $0.95 per share of Common Stock, subject to adjustments as provided under the terms of the May 2023 Warrants. The May 2023 Warrants have a term of five years from the date of issuance. The May 2023 Private Placement closed on May 24, 2023. The Company received gross proceeds of approximately $3.5 million before deducting transaction related fees and expenses payable by the Company.

 

In connection with the May 2023 Private Placement, the Company entered into a Registration Rights Agreement with the investor. The Company’s registration statement on Form S-3 to register the securities issued in the May 2023 Private Placement went effective on June 5, 2023.

 

Transaction costs incurred related to the May 2023 Private Placement include the following: (i) placement agent fees of $316,850, and (ii) legal expenses of $78,400.

 

Warrants

 

September 2022 Warrants

 

In the Company’s September 2022 Private Placement, Warrants to purchase up to 9,523,810 shares of Common Stock were issued (“September 2022 Warrants”). The September 2022 Warrants were initially exercisable at a price of $1.05 per share, subject to adjustment as set forth in the September 2022 Warrants, at any time after September 12, 2022 and will expire on September 13, 2027. In connection with the May 2023 Private Placement, the exercise price of the September 2022 Warrants issued in the September 2022 Private Placement was reduced to $0.95 per share.

 

21
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

11. Stockholders’ Equity (continued)

 

The fair value of the September 2022 Warrants immediately prior to the modification was $7,399,000, and the fair value of the September 2022 Warrants immediately after the modification was $6,901,000, representing a decrease in fair value of $498,000. In accordance with ASU 2021-04, as the modification was a result of issuing equity and there was no increase in fair value, the Company accounted for the adjustment as a reduction of additional paid-in capital with a corresponding offset recorded to additional paid-in capital (i.e., net impact to additional paid-in capital of $nil).

 

May 2023 Warrants

 

In the Company’s May 2023 Private Placement, Warrants to purchase up to 3,684,210 shares of Common Stock were issued (“May 2023 Warrants”). The fair value of the May 2023 Warrants was determined utilizing a Black Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $0.78, exercise price of $0.95, term of five years, volatility of 165.0%, risk-free rate of 3.8%, and dividend rate of 0.0%). The grant date fair value of the May 2023 Warrants was estimated to be $1.6 million on May 24, 2024 and is reflected within additional paid-in capital as of June 30, 2023.

 

During the six months ended June 30, 2022, the Company issued the following:

 

  - 12,500 shares of common stock at a purchase price of $4.00 per share, for gross cash proceeds of $50,000, to one accredited investor in January 2022;
     
  - 500,000 shares of common stock for services rendered, at a fair value of $4.00 per share determined using the per share purchase price of the latest $4.00 private placement Round, to the Chief Financial Officer of the Company, in April 2022;
     
  - 1,574,490 shares of common stock for services rendered, at a fair value of $8.00 per share determined using the per share purchase price of the latest $8.00 private placement Round, to six consultants in April 2022;
     
  - 5,000 shares of common stock that were issued in January 2021 to a director of the Company, for services valued at $2.00 per share determined using the per share purchase price of the $2.00 Round, were canceled in April 2022;
     
  - 300,000 shares of common stock at a purchase price of $10.00 per share, for gross cash proceeds of $3,000,000, to two accredited investors in May 2022; and
     
  - 108,000 shares of common stock that were issued in June 2019 to a consultant of the Company, for services valued at $0.069 per share determined using an asset approach, were canceled in June 2022.

 

22
 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

12. Related Party Transactions

 

Other than the transactions disclosed elsewhere in the condensed financial statements, the following are the other significant related party transactions and balances:

 

Included in common stock issued for services during the six months ended June 30, 2023, were 1,750,000 shares of common stock issued to the Executive Chairman of the Company (Note 11).

 

Included in common stock issued for services during the six months ended June 30, 2023, were 500,000 shares of common stock issued to the Chief Executive Officer of the Company (Note 11).

 

At June 30, 2023, $800,000 was due to the Company’s former interim Chief Executive Officer, who is also the Company’s Executive Chairman. The amount, which includes $750,000 in accrued bonus, is included in accrued liabilities in the condensed balance sheet. The accrued bonus is expected to be paid in the first quarter of 2024 and is subject to Board of Director approvals.

 

At June 30, 2023, $75,000 was due to the Company’s Chief Executive Officer. The amount is included in accrued liabilities in the condensed balance sheet.

 

At June 30, 2023, $23,201 was due to a company majority owned by the Company’s Chief Executive Officer. The amount is included in accounts payable in the condensed balance sheets.

 

At June 30, 2023, $24,480 was due to a company wholly owned by the Company’s Chief Financial Officer, who also is a shareholder. The amount is included in accounts payable in the condensed balance sheet.

 

At June 30, 2023, the outstanding balance on the related party line of credit note of $3,561,657 was due to a Lender, who is a member of the Board (Note 10). The amount is included in the related party line of credit note in the condensed balance sheet.

 

13. Contingencies

 

In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the condensed financial statements.

 

Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company. Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The case is in the discovery phase. The Company is exploring potential dispositive motions against the counter and third-party claims.

 

Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of Bright Green Grown Innovation LLC. The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.

 

14. Subsequent Events

 

The Company’s management has evaluated the subsequent events up to August 16, 2023, the date the financial statements were issued, pursuant to the requirements of ASC 855, and has determined that the following constitute material subsequent events:

 

On July 31, 2023, the Company issued 137,838 shares to a consultant for professional services, pursuant to the terms of a consulting services agreement. 

 

23
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed financial statements and the accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements based upon current plans, expectations, and beliefs, involving risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements. You should review the sections titled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” in this Quarterly Report, our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and other periodic reports filed with the Securities and Exchange Commission (the “SEC”) for discussions of forward-looking statements and factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis, and elsewhere in this Quarterly Report on Form 10-Q. Our historical results are not necessarily indicative of the results that may be expected for any period in the future.

 

Overview

 

Bright Green Corporation (“Company”, “BGC”, “Bright Green”, “we”, “us”, or “our”) is a first-mover in the U.S. federally-authorized cannabis space. BGC is one of a few companies who have received from the U.S. Drug Enforcement Administration (the “DEA”), a federal controlled substances registration for the bulk manufacturing of cannabis under DEA Registration No. RB0649383 (the “DEA Registration”), which allows the Company to produce federally legal cannabis, cannabis extracts, and tetrahydrocannabinol in the U.S. We received the DEA Registration on April 28, 2023, pursuant to the Memorandum of Agreement (the “MOA”) with the DEA entered into on April 27, 2023, which replaced the 2021 Memorandum of Agreement (the “2021 MOA”) (DEA Document Control Number W20078135E).

 

Unlike state-licensed cannabis companies who engage in commercial sales to consumers, and whose businesses are legal under state law but not federal law, subject to the milestones and requirements set forth herein, we are authorized by the federal government to sell cannabis commercially for research and manufacturing purposes, export cannabis for international cannabis research purposes, and sell cannabis to DEA-registered pharmaceutical companies for the production of medical cannabis products and preparations. Our business activities under the DEA Registration are subject to applicable federal law and regulations and to our obligations under the MOA we entered into with the DEA. Our DEA Registration is valid through July 31, 2024. We plan to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of CBN (cannabinol) and CBG (cannabigerol).

 

In addition to research and pharmaceutical supply sales, Bright Green will be able to sell certain cannabinoids, such as CBN (cannabinol) and CBG (cannabigerol) as hemp isolates or extracts, and plans to sell CBN and CBG hemp products to consumers where such products are fully legal under all applicable laws. On August 9, 2022, the DEA confirmed to BGC that cannabinoids, including, but not limited to CBN/CBG, which meet the definition of “hemp” by having a Delta-9-tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis, are outside of the DEA’s jurisdiction because they are not controlled under the CSA. Hemp and hemp products were made legal by the Agriculture Improvement Act of 2018 (the “2018 Farm Bill”), which has been codified in 21 U.S.C. § 802(16)(B)(i), and 7 U.S.C. § 1639o. This hemp product business line will be in addition to our research and pharmaceutical cannabis activities conducted under the DEA Registration.

 

Because cannabis is still a Schedule I controlled substance in the U.S., it has been historically under-researched. Though the majority of Americans now live in states where cannabis is legal, the full potential of the cannabis plant for medicinal use remains understudied due to limited access to federally-approved cannabis. The DEA recently issued a call for more cannabis research supply based on the increased demand for cannabis research in the U.S. As described herein, on April 28, 2023, we received the DEA Registration, which allows us to produce federally legal cannabis, cannabis extracts, and tetrahydrocannabinol and to sell legally within the U.S. to licensed researchers and pharmaceutical companies, in addition to qualifying us to export cannabis internationally.

 

24
 

 

BGC must comply with the terms agreed upon pursuant to the MOA which include: submitting an Individual Procurement Quota on or before April 1 of each year utilizing DEA Form 250; submitting an Individual Manufacturing Quota on or before May 1 of each year utilizing DEA Form 189; collecting samples of cannabis and distributing them to DEA-registered analytical laboratories for chemical analysis during the pendency of cultivation and prior to the DEA’s taking possession of the cannabis grown; providing the DEA with 15-day advance written notification, via email, of its intent to harvest cannabis; following the DEA’s packaging, labeling, storage and transportation requirements; distributing DEA’s stocks of cannabis to buyers who entered into bona fide supply agreements with the Company; providing the DEA with 15-day advance written notification of its intent to distribute cannabis; and invoicing the DEA for harvested cannabis that it intends to sell to the DEA.

 

Having received our DEA Registration, we are permitted to cultivate and manufacture cannabis, supply cannabis researchers in the U.S. and globally, and produce cannabis for use in pharmaceutical production of prescription medicines within the U.S. Our DEA Registration permits our cannabis activities under federal law, which sets BGC apart from most other U.S. cannabis companies.

 

We have assembled an experienced team of medical professionals and researchers, international horticultural growers and experts, and construction and cannabis production professionals, which we believe position us as a future industry leader in the production of cannabis.

 

Recent Developments

 

None.

 

Results of Operations

 

This section includes a summary of our historical results of operations, followed by detailed comparisons of our results for the three and six months ended June 30, 2023 and June 30, 2022.

 

The Company has not started commercial operations but has incurred expenses in connection with corporate and administrative matters, upkeep of acquired properties for future growing, processing and distribution of medical plants, and improvements to those properties. These expenses include stock-based compensation for services rendered, legal and audit fees, and property-related expenses such as depreciation, insurance and taxes. As a result, the Company reported a net loss both reporting periods.

 

25
 

 

Three and six months ended June 30, 2023 compared to three and six months ended June 30, 2022. 

 

Revenue:

 

We are a start-up company and have not generated any revenues for the three and six months ended June 30, 2023 and 2022. We can provide no assurance that we will generate sufficient revenues from our intended business operations to sustain a viable business operation.

 

Operating Expenses:

 

We incurred operating expenses in the amount of $2,986,506 for the three months ended June 30, 2023, as compared with $19,181,093 for the same period ended 2022. We incurred operating expenses in the amount of $5,599,129 for the six months ended June 30, 2023, as compared with $19,907,439 for the same period ended 2022. Our operating expenses for all periods consisted entirely of general and administrative expenses and depreciation. The detail by major category within general and administrative expenses for the three and six months ended June 30, 2023 and 2022 is reflected in the table below.

 

   Three Months Ended   Six Months Ended 
   June 30, 2023   June 30, 2022   June 30, 2023   June 30, 2022 
                 
Stock-based compensation  $1,448,750   $14,578,468   $2,272,650   $14,578,468 
Professional fees   720,478    4,069,967    1,646,571    4,532,173 
Officer salaries   464,549    -    945,306    - 
Other expenses   118,360    88,370    241,893    99,435 
Insurance   37,405    33,602    78,311    46,903 
Travel   23,201    120,691    63,016    132,337 
Property taxes   14,528    14,498    29,056    28,997 
Licenses   25    70,335    5,575    81,658 
Land option   -    10,500    -    21,000 
Total general and administrative expenses  $2,827,296   $18,986,431   $5,282,378   $19,520,971 
Depreciation   159,210    194,662    316,751    386,468 
Total operating expenses  $2,986,506   $19,181,093   $5,599,129   $19,907,439 

 

The decrease of $16,159,135 and $14,238,593 in our general and administrative expenses for the three and six months ended June 30, 2023, respectively, versus the same periods ended 2022 is largely the result of decreased spending on stock-based compensation to executives and professional fees associated with the Direct Listing.

 

We expect our general and administrative expenses to increase in future quarters as we continue with our reporting obligations with the SEC and the increased expenses associated with increased operational activity, which is expected for the balance of the year.

 

Liquidity and Capital Resources

 

As of June 30, 2023, the Company had cash of $507,445 compared to $414,574 as of December 31, 2022. The increase of $92,871 in cash was mainly by cash received from the sales of units of $3,104,750, $880,000 through the sales of common stock from the Company’s EB-5 Program, $210,000 from the exercise of warrants, and $200,000 from a draw on the line of credit. This was partly offset by the use of funds for the construction in progress, deposits for equipment, and the costs associated with the Company’s SEC filings. Since its inception, the Company has incurred net losses and funded its operations primarily through the issuance of equities, an advance from a director, and draws on the line of credit provided by a Director of the Company. As of June 30, 2023, the Company had a total stockholders’ equity of $13,320,800 (December 31, 2022 - $11,578,836).

 

The Company is in its initial stages to start building facilities to grow, research and distribute medical plants. The Company has incurred recurring losses from operations, and as of June 30, 2023, had an accumulated deficit of $39,681,257 (December 31, 2022 - $34,075,821), and a negative working capital of $7,314,852 (December 31, 2022 – $7,030,929). The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the condensed financial statements were authorized to be issued. The Company’s continued existence is dependent upon its ability to continue to execute its operating plan and to obtain additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan. During the three months ended June 30, 2023, the Company raised $3,104,750 through unit issuances. The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove accurate in all material respects, or that the Company will be able to successfully execute its operating plan. In the event that the Company is not able to raise capital from investors or credit facilities in a timely manner, the Company will explore available options, including but not limited to, an equity backed loan against the property. In the absence of additional appropriate financing, the Company may have to modify its plan or slow down the pace of development and commercialization.

 

Inflation

 

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the six months ended June 30, 2023.

 

Off-balance sheet arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily available apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a detailed discussion about the Company’s significant accounting policies, refer to Note 3 “Summary of Significant Accounting Policies,” in the Company’s condensed financial statements included in this Quarterly Report on Form 10-Q. During the six months ended June 30, 2023, no material changes were made to the Company’s significant accounting policies.

 

JOBS Act Accounting Election

 

We are an emerging growth company, as defined in the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period under the JOBS Act until the earlier of the date we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our condensed financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

The Company believes that it is not subject to material foreign currency exchange rate fluctuations, as substantially all of its sales and expenses are denominated in the U.S. dollar. The Company does not hold derivative securities and has not entered into contracts embedded with derivative instruments, such as foreign currency and interest rate swaps, options, forwards, futures, collars or warrants, either to hedge existing risks or for speculative purposes.

 

26
 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer has evaluated the effectiveness of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

Under the supervision and with the participation of our management, including our former Interim Chief Executive Officer and Chief Financial Officer, we conducted an assessment of the effectiveness of our internal control over financial reporting as of June 30, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material error in our annual or interim financial statements will not be prevented or detected on a timely basis. In Management’s Report on Internal Control over Financial Reporting included in our quarterly report on Form 10-Q for the quarter ended June 30, 2022, (the “Original June Report”) filed with the SEC on August 12, 2022, our management previously concluded that we maintained effective internal control over financial reporting as of June 30, 2022. On August 16, 2022, management determined that we made certain errors related to the fair value recorded for shares issued for services rendered in June 2022. The fair value of such shares is $8.00 per share but was recorded as $4.00 per share in the Original June Report. As a result, we determined that there were material errors in the financial information that required an amendment to our Original June Report (the “June Amendment”). With this error being corrected in the June Amendment filed with the SEC on August 19, 2022, net loss increased by $6,297,960. We have strengthened our review controls around the issuance of shares of common stock and the recording of the associated expense by adding an additional reviewer to the review process. The Company continues to evaluate and implement procedures as deemed appropriate to enhance our disclosure controls.

 

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. As required by Rule 13a-15(b) of the Exchange Act, an evaluation as of June 30, 2023 was conducted under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on this evaluation as of June 30, 2023, our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of the period ended June 30, 2023.

 

Changes in Internal Control Over Financial Reporting

 

There has been no change in our internal control over financial reporting during the quarter ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Inherent Limitations on Effectiveness of Controls

 

Management recognizes that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

27
 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may be involved in legal proceedings arising from the normal course of business activities. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

ITEM 1A. RISK FACTORS

 

An investment in our securities involves a high degree of risk, including those risks described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022, which we encourage you to review. There have been no material changes from the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 17, 2023 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 filed with the SEC on May 22, 2023. If any of these risks are realized, our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price of our securities could decline and you could lose all or part of your investment in our securities. Additional risks of which we are not presently aware or that we currently believe are immaterial may also harm our business and results of operations. Some statements in this Quarterly Report on Form 10-Q, including such statements in the following risk factors, constitute forward-looking statements. See the section entitled “Cautionary Note Regarding Forward-Looking Statements” for more information.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

 

During the period from April 1, 2023 through the date hereof, the Company issued the following:

 

  3,684,210 shares of common stock and warrants to purchase up to an aggregate of 3,684,210 shares of common stock, at a combined purchase price of $0.95 per share of common stock and accompanying warrant, in a private placement offering, to one accredited investor.

 

The Company relied upon the exemption provided by Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act in connection with issuance and sale of the securities described above. The person who acquired these shares was a sophisticated investor and was provided full information regarding the Company’s business and operations. There were no general solicitations in connection with the offer or sale of these securities. The person who acquired these securities acquired them for their own account.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

Given the timing of events, the following information is included in this Form 10-Q pursuant to Item 5.02 of Form 8-K “Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers” in lieu of filing a Form 8-K:

 

Our Chief Executive Officer, Seamus McAuley, has taken a brief medical leave of absence. Mr. McAuley’s temporary leave of absence is due to health reasons and required medical treatment and not any disagreement with us on any matter related to our operations, policies or practices. As of the filing date of this Quarterly Report on Form 10-Q, Mr. McAuley remains on a medical leave of absence. As resolved by the Company’s board of directors on August 14, 2023, Terry Rafih, the Company’s Executive Chairman, has been named acting Principal Executive Officer and has assumed all of Mr. McAuley’s authority and responsibilities with respect to such role, until Mr. McAuley returns from his temporary leave of absence. Mr. Rafih’s compensation as Executive Chairman of the Company shall remain unchanged.

 

28
 

 

ITEM 6. EXHIBITS

 

Exhibit

Number

  Description
     
4.1   Form of Warrant, filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 24, 2023.
10.1   Memorandum of Agreement, dated April 27, 2023, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 4, 2023.
10.2   Addendum to Memorandum of Agreement, dated April 27, 2023, filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on May 4, 2023.
10.1#   Securities Purchase Agreement dated May 21, 2023, by and between the Company and the purchasers thereto, filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 24, 2023.
10.2   Registration Rights Agreement dated May 24, 2023, by and between the Company and the purchasers thereto, filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on May 24, 2023.
10.3   Placement Agency Agreement dated May 21, 2023 by and between the Company and EF Hutton, division of Benchmark Investments, LLC, filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on May 24, 2023.
31.1*   Certification of the Principal Executive Officer pursuant to Exchange Act Rule 13a-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of the Principal Financial Officer pursuant to Exchange Act Rule 13a-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*†   Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*†   Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS*   Inline XBRL Instance Document.
     
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
     
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
     
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document in Exhibit 101)

 

# Certain schedules and exhibits have been omitted pursuant to Item 601(A)(5) of Regulation S-K. The Company will furnish supplementally copies of omitted schedules and exhibits to the Securities and Exchange Commission or its staff upon its request.

 

* Filed herewith.

 

The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

 

29
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  BRIGHT GREEN CORPORATION
     
Date: August 16, 2023 By: /s/ Saleem Elmasri
    Saleem Elmasri
    Chief Financial Officer

 

30

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Terry Rafih, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 of Bright Green Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 16, 2023

 

    /s/ Terry Rafih
  Name: Terry Rafih
  Title: Executive Chairman
    (Principal Executive Officer)

 

 

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

I, Saleem Elmasri, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 of Bright Green Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 16, 2023

 

    /s/ Saleem Elmasri
  Name: Saleem Elmasri
  Title: Chief Financial Officer
    (Principal Financial Officer)

 

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Bright Green Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023 (the “Report”), I, Terry Rafih, the Executive Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

    /s/ Terry Rafih
  Name: Terry Rafih
  Title:

Executive Chairman

(Principal Executive Officer)

 

Date: August 16, 2023

 

 

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Bright Green Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023 (the “Report”), I, Saleem Elmasri, the Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

  (1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
     
  (2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

    /s/ Saleem Elmasri
  Name: Saleem Elmasri
  Title: Chief Financial Officer
    (Principal Financial Officer)

 

Date: August 16, 2023

 

 

v3.23.2
Cover - shares
6 Months Ended
Jun. 30, 2023
Aug. 16, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41395  
Entity Registrant Name BRIGHT GREEN CORPORATION  
Entity Central Index Key 0001886799  
Entity Tax Identification Number 83-4600841  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 1033 George Hanosh Boulevard  
Entity Address, City or Town Grants  
Entity Address, State or Province NM  
Entity Address, Postal Zip Code 87020  
City Area Code (833)  
Local Phone Number 658-1799  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol BGXX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   179,620,858
Entity Information, Former Legal or Registered Name Not Applicable  
v3.23.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets    
Cash $ 507,445 $ 414,574
Prepaid expenses and other assets 182,117 77,847
Total current assets 689,562 492,421
Deposits (Notes 5 and 9) 1,109,643 1,157,587
Equity method investment (Note 6) 3,986,019 3,990,960
Property, plant, and equipment (Note 7) 19,100,647 17,146,325
Intangible assets (Note 8) 1,000 1,000
Total assets 24,886,871 22,788,293
Current liabilities    
Accounts payable (Note 12) 5,408,503 5,033,831
Accrued liabilities (Note 12) 945,911 447,325
Due to others (Note 6) 1,650,000 1,650,000
Total current liabilities 8,004,414 7,523,350
Long-term liabilities    
Related party line of credit note (Notes 10 and 12) 3,561,657 3,686,107
Total long-term liabilities 3,561,657 3,686,107
Total liabilities 11,566,071 11,209,457
STOCKHOLDERS’ EQUITY    
Common stock; $.0001 par value; 500,000,000 stock authorized; 179,483,020 and 173,304,800 stock issued and outstanding at June 30, 2023 and December 31, 2022, respectively (Note 11) 17,948 17,329
Additional paid-in capital (Note 11) 52,984,109 45,637,328
Accumulated deficit (39,681,257) (34,075,821)
Total stockholders’ equity 13,320,800 11,578,836
Total liabilities and stockholders’ equity 24,886,871 22,788,293
Related Party [Member]    
Current liabilities    
Due to related party (Note 10) $ 392,194
v3.23.2
Condensed Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 179,483,020 173,304,800
Common stock, shares outstanding 179,483,020 173,304,800
v3.23.2
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenue
Expenses        
General and administrative expenses 2,827,296 18,986,431 5,282,378 19,520,971
Depreciation 159,210 194,662 316,751 386,468
Total operating expenses 2,986,506 19,181,093 5,599,129 19,907,439
Loss from operations (2,986,506) (19,181,093) (5,599,129) (19,907,439)
Other expense        
Foreign currency transaction loss 724 1,366
Total other expense 724 1,366
Loss before income taxes and equity in net losses of affiliate (2,987,230) (19,181,093) (5,600,495) (19,907,439)
Income tax expense
Loss before equity in net losses of affiliate (2,987,230) (19,181,093) (5,600,495) (19,907,439)
Equity in net losses of affiliate (Note 6) (4,941) (4,941)
Net loss and comprehensive loss $ (2,992,171) $ (19,181,093) $ (5,605,436) $ (19,907,439)
Weighted average common shares outstanding - basic 176,240,466 158,901,214 174,851,640 158,231,923
Weighted average common shares outstanding - diluted 176,240,466 158,901,214 174,851,640 158,231,923
Net loss per common share - basic $ (0.02) $ (0.12) $ (0.03) $ (0.13)
Net loss per common share - diluted $ (0.02) $ (0.12) $ (0.03) $ (0.13)
v3.23.2
Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 15,754 $ 14,618,389 $ (6,413,744) $ 8,220,399
Balance, shares at Dec. 31, 2021 157,544,500      
Balance at Mar. 31, 2022 $ 15,755 14,668,388 (7,140,090) 7,544,053
Balance, shares at Mar. 31, 2022 157,557,000      
Balance at Dec. 31, 2021 $ 15,754 14,618,389 (6,413,744) 8,220,399
Balance, shares at Dec. 31, 2021 157,544,500      
Common stock issued for services (Note 11) $ 207 14,595,713 14,595,920
Common stock issued for services (Note 11), shares 2,074,490      
Net loss (19,907,439) (19,907,439)
Common stock issued for cash (Note 11) $ 31 3,049,969 3,050,000
Common stock issued for cash (Note 11), shares 312,500      
Common stock cancelled that was issued for services (Note 11) $ (11) (17,441) (17,452)
Common stock cancelled that was issued for services (Note 11), shares (113,000)      
Balance at Jun. 30, 2022 $ 15,981 32,246,630 (26,321,183) 5,941,428
Balance, shares at Jun. 30, 2022 159,818,490      
Balance at Mar. 31, 2022 $ 15,755 14,668,388 (7,140,090) 7,544,053
Balance, shares at Mar. 31, 2022 157,557,000      
Common stock issued for services (Note 11) $ 207 14,595,713 14,595,920
Common stock issued for services (Note 11), shares 2,074,490      
Net loss (19,181,093) (19,181,093)
Common stock issued for cash (Note 11) $ 30 2,999,970 3,000,000
Common stock issued for cash (Note 11), shares 300,000      
Common stock cancelled that was issued for services (Note 11) $ (11) (17,441) (17,452)
Common stock cancelled that was issued for services (Note 11), shares (113,000)      
Balance at Jun. 30, 2022 $ 15,981 32,246,630 (26,321,183) 5,941,428
Balance, shares at Jun. 30, 2022 159,818,490      
Balance at Dec. 31, 2022 $ 17,329 45,637,328 (34,075,821) 11,578,836
Balance, shares at Dec. 31, 2022 173,304,800      
Balance at Mar. 31, 2023 $ 17,441 48,431,116 (36,689,086) 11,759,471
Balance, shares at Mar. 31, 2023 174,423,810      
Balance at Dec. 31, 2022 $ 17,329 45,637,328 (34,075,821) 11,578,836
Balance, shares at Dec. 31, 2022 173,304,800      
Common stock and warrants issued for cash in a private placement, net of issuance costs of $395,250 (Note 11) $ 368 3,104,382 3,104,750
Common stock and warrants issued for cash in a private placement, net of issuance costs of $395,250 (Note 11), shares 3,684,210      
Common stock issued for services (Note 11) $ 227 2,272,423 2,272,650
Common stock issued for services (Note 11), shares 2,250,000      
Net loss (5,605,436) (5,605,436)
Warrants exercised for cash (Note 11) $ 20 209,980 210,000
Warrants exercised for cash (Note 11), shares 200,000      
Common stock issued for a cashless conversion from related party LOC for EB-5 program (Note 11) $ 2 879,998 880,000
Common stock issued for a cashless conversion from related party LOC for EB-5 program (Note 11), shares 22,005      
Common stock issued for cash for EB-5 program (Note 11) $ 2 879,998 880,000
Common stock issued for cash for EB-5 program (Note 11), shares 22,005      
Balance at Jun. 30, 2023 $ 17,948 52,984,109 (39,681,257) 13,320,800
Balance, shares at Jun. 30, 2023 179,483,020      
Balance at Mar. 31, 2023 $ 17,441 48,431,116 (36,689,086) 11,759,471
Balance, shares at Mar. 31, 2023 174,423,810      
Common stock and warrants issued for cash in a private placement, net of issuance costs of $395,250 (Note 11) $ 368 3,104,382 3,104,750
Common stock and warrants issued for cash in a private placement, net of issuance costs of $395,250 (Note 11), shares 3,684,210      
Common stock issued for services (Note 11) $ 139 1,448,611 1,448,750
Common stock issued for services (Note 11), shares 1,375,000      
Net loss (2,992,171) (2,992,171)
Balance at Jun. 30, 2023 $ 17,948 $ 52,984,109 $ (39,681,257) $ 13,320,800
Balance, shares at Jun. 30, 2023 179,483,020      
v3.23.2
Condensed Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Statement of Stockholders' Equity [Abstract]    
Issuance costs $ 395,250 $ 395,250
v3.23.2
Condensed Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (5,605,436) $ (19,907,439)
Adjustments to reconcile net cash used in operating activities:    
Equity in net losses of affiliate 4,941
Depreciation 316,751 386,468
Stock-based compensation 2,272,650 14,578,468
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (104,270) 62,700
Accounts payable 374,672 1,252,950
Accrued liabilities 498,586 87,580
Accrued interest 163,356
Net cash used in operating activities (2,078,750) (3,539,273)
CASH FLOWS FROM INVESTING ACTIVITIES    
Deposits 47,944
Purchase of property, plant, and equipment (2,271,073) (2,614,319)
Net cash used in investing activities (2,223,129) (2,614,319)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from related party line of credit 200,000 2,000,000
Proceeds from issuance of common stock 880,000 3,050,000
Proceeds from issuance of common stock and warrants, issued in private placement, net of issuance costs 3,104,750
Proceeds from warrants exercised 210,000
Net cash provided by financing activities 4,394,750 5,050,000
NET INCREASE (DECREASE) IN CASH 92,871 (1,103,592)
CASH, BEGINNING OF PERIOD 414,574 1,282,565
CASH, END OF PERIOD 507,445 178,973
CASH PAID FOR    
Interest
Taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES    
Transfer from due to related party to related party LOC 392,194
Related party LOC in exchange for common stock for EB-5 program $ (880,000)
v3.23.2
Description of Business and Organization
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business and Organization

1. Description of Business and Organization

 

Bright Green Corporation (the “Company,” “our,” “us,” “we,” or “Bright Green”) was incorporated on April 16, 2019, under the Delaware General Corporation Law. The Company’s principal executive office is located in Grants, New Mexico. The Company holds the land, greenhouse and patents required in the growth, production, and research of medicinal plants.

 

On March 29, 2022, the Company filed a registration statement pursuant to the Securities Act of 1933, as amended (the “Securities Act”) on Form S-1 with the Securities and Exchange Commission (“SEC”), which was declared effective May 13, 2022, (as amended, the “Registration Statement”), in connection with the direct listing of the Company’s common stock with the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”).

 

On May 17, 2022, the Company’s common stock commenced trading on Nasdaq under the symbol “BGXX.”

 

On February 1, 2023, the Company initiated a private placement offering of our common stock, only to accredited or qualified institutional investors, in reliance upon Rule 506, Regulation D promulgated under the Securities Act, pursuant to the U.S. government’s EB-5 immigrant investor program. Under our EB-5 Program, we may issue up to an aggregate of 12,609,152 shares of common stock at $39.99 per share.

 

On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company for the sale by the Company of (i) 3,684,210 shares of the Company’s common stock, par value $0.0001 per share, and (ii) warrants to purchase up to an aggregate of 3,684,210 shares of the Company’s common stock, in a private placement offering. The combined purchase price of one share and accompanying warrant was $0.95. The shares and the warrants were sold and issued without registration under the Securities Act of 1933, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 of Regulation D promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.

 

The Company is a start-up company at June 30, 2023 and has no revenue.

 

v3.23.2
Going Concern and Basis of Presentation
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern and Basis of Presentation

2. Going Concern and Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cashflows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations.

 

The financial information contained in this report should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which the Company filed on April 17, 2023. The results of operations for the six months ended June 30, 2023 are not necessarily indicative of the results for the year ending December 31, 2023.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

2. Going Concern and Basis of Presentation (continued)

 

For the six months ended June 30, 2023 and 2022, the Company had no revenues from product sales and incurred a net loss of $5,605,436 and $19,907,439, respectively. Net cash used in operations for the six months ended June 30, 2023, and 2022 was $2,078,750 and $3,539,273, respectively. The Company has incurred recurring losses from operations, and as of June 30, 2023, had an accumulated deficit of $39,681,257 (December 31, 2022 – $34,075,821) and had a negative working capital of $7,314,852 (December 31, 2022 – $7,030,929).

 

The Company is in its initial stages of building facilities to grow, research, and distribute medical plants. The Company has historically financed its operations through the sale of equity securities and debt financing. The Company does not have sufficient working capital to pay its operating expenses for a period of at least 12 months from the date the condensed financial statements were authorized to be issued. Therefore, the Company’s continued existence depends on its ability to continue executing its operating plan and obtaining additional debt or equity financing. The Company has developed plans to raise funds and continues to pursue sources of funding that management believes, if successful, would be sufficient to support the Company’s operating plan.

 

During the six months ended June 30, 2023, the Company raised $3,104,750 through the issuance of common stock and accompanying warrants to purchase shares of common stock from the Company’s private placement offering in May 2023, $880,000 through common stock issuances from the Company’s EB-5 Program, and $210,000 through the exercise of warrants. The Company also has drawn $200,000 from the Company’s $15,000,000 line of credit from a related party. The Company also had two cashless conversions, the related party line of credit was used to pay in full the related party loan balance of $392,194, and the related party line of credit was paid down $880,000 in exchange for 22,005 shares of the Company’s common stock valued at $39.99 per share according to the Company’s EB-5 Program, leaving available $11.4 million to draw from that credit facility (Note 10). However, there is substantial doubt about the Company’s ability to continue as a going concern due to the necessity to generate positive cash flows from operations and/or obtain additional financing. There is no assurance that the Company will be able to generate positive cash flows from operations or obtain additional financing on terms acceptable to the Company, if at all.

 

In addition, the Company’s current and future operations are subject to various risks and uncertainties, including but not limited to general economic conditions, competition, and regulatory matters. Accordingly, the Company’s operation plan is predicated on various assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue raising additional financing, and the state of the general economic environment in which the Company operates.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

2. Going Concern and Basis of Presentation (continued)

 

These risks and uncertainties may have a material adverse effect on the Company’s financial condition and operating results. Management has taken actions to address the Company’s liquidity needs, including managing expenses, developing pathways to revenue, and pursuing additional financing, such as the EB-5 Capital Program announced on February 1, 2023. However, there can be no assurance that such actions will be sufficient to enable the Company to continue as a going concern. There can be no assurance that these assumptions will prove accurate in all material respects or that the Company will be able to successfully execute its operating plan.

 

The condensed financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. In addition, the Company does not have any short or long-term contractual purchases with suppliers for future purchases, capital expenditure commitments that cannot be canceled with minimal fees, noncancelable operating leases, or any commitment or contingency that would hinder management’s ability to scale down operations and management expenses until funding is raised.

 

The Company’s ability to continue as a going concern is dependent upon the outcome of the matters described above. The condensed financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

This disclosure is intended to inform users of the condensed financial statements about the Company’s current financial condition and its ability to continue as a going concern. The Company will continue to monitor its liquidity position and take appropriate actions as necessary to address any potential going concern issues.

 

v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

 

  A. Basis of Measurement

 

The condensed financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.

 

  B. Property, Plant, and Equipment

 

Property, plant, and equipment is stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant, and equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  B. Property, Plant, and Equipment (continued)

 

  Building and improvement - declining balance method 10 year life
  Furniture and fixtures - straight-line method 3 year life

 

Construction in progress is not depreciated until the asset is placed in service.

 

  C. Long-lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

 

  D. Intangible Assets

 

The Company’s intangible assets consist of certain licenses (Note 8) which will be amortized over the term of each license. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

 

  E. Fair Value of Financial Instruments

 

In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

 

  Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  E. Fair Value of Financial Instruments (continued)

 

  Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and
     
  Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of June 30, 2023 and December 31, 2022 due to their short-term nature.

 

   F. Investments Under the Equity Method

 

When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. In addition, the Company may recognize its share of an investee’s earnings based on an estimated amount for the investee’s earnings when the investee’s financial information is not sufficiently timely for the Company’s reporting period.

 

Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.

 

Derivative Financial Instruments

 

The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the condensed statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s condensed balance sheets.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  G. Advertising Costs

 

Advertising costs are charged to operations when incurred. Advertising costs totaled $20,333 and $35,857 for the six months ended June 30, 2023 and 2022, respectively.

 

  H. Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed its methodology for estimating the valuation allowance. A change in valuation allowance affects earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

  I. Basic and Diluted Earnings (Loss) per share

 

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  J. Segment Reporting

 

ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s condensed financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at June 30, 2023 and 2022 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.

 

  K. Use of Estimates

 

The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, going concern assessment, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

  L. Stock-based Compensation

 

The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the condensed statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  L. Stock-based Compensation (continued)

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.

 

  M. Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each condensed balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed statements of operations and comprehensive loss.

 

  N. Standards, Amendments, and Interpretations Adopted

 

  1) Modification of Equity-Classified Written Call Options

 

In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (here-after referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  N. Standards, Amendments, and Interpretations Adopted (continued)

 

  1) Modification of Equity-Classified Written Call Options (continued)

 

to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods within those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.

 

  2) Leases

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.

 

The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.

 

A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of June 30, 2023, the Company has one month to month lease, whereas the new standard does not apply.

 

  3) Fair Value Measurement

 

In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).

v3.23.2
Concentration of Credit Risk
6 Months Ended
Jun. 30, 2023
Risks and Uncertainties [Abstract]  
Concentration of Credit Risk

4. Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $271,268 and $187,821 in excess of the FDIC insured limit at June 30, 2023 and December 31, 2022, respectively.

 

v3.23.2
Deposits
6 Months Ended
Jun. 30, 2023
Deposits

5. Deposits

 

As of December 31, 2022, deposits were comprised of one down payment for a construction of equipment contract for which the Company had not yet taken title and one down payment for a construction contract for which the work had not started. As of June 30, 2023, the Company has still not taken title of the equipment and the construction contract was completed (Note 9).

 

v3.23.2
Equity Method Investment in Alterola
6 Months Ended
Jun. 30, 2023
Investments, All Other Investments [Abstract]  
Equity Method Investment in Alterola

6. Equity Method Investment in Alterola

 

On October 3, 2022, the Company entered into a Secondary Stock Purchase Agreement and Release (the “Secondary SPA”) with Phytotherapeutix Holdings Ltd., a United Kingdom entity, Equipped4 Holdings Limited, a United Kingdom entity, TPR Global Limited, a United Kingdom entity (each, a “Seller” and collectively, the “Sellers”) and Alterola Biotech Inc., a Nevada corporation (“Alterola”) providing for the purchase by Bright Green of shares of Common Stock of Alterola from the Sellers (the “Transferred Shares”).

 

The Secondary SPA provides that, as of the date thereof, the authorized shares of Alterola consist of 2,000,000,000 shares of common stock, $0.001 par value, of which 807,047,948 shares are issued and outstanding. The Sellers Transferred Shares consisted of, in aggregate, 201,761,982 shares of Common Stock, which were sold to Bright Green for a purchase price of $3,999,999, pursuant to the payment schedule set forth in the Secondary SPA. As of June 30, 2023 and December 31, 2022, the Company has a liability to the Sellers of $1,650,000, which is in default at June 30, 2023. The Company is currently negotiating a new agreement with the Sellers to resolve the issue. The liability is not interest bearing and not secured. Following the receipt of each installment payment, the Sellers agreed to loan to Alterola the proceeds such Seller received from the foregoing sale of its Transferred Shares, pursuant to a loan agreement.

 

The Sellers held 67% of Alterola’s total outstanding shares prior to the closing of the Secondary SPA. As a result of this transaction, Bright Green obtained ownership or voting power of approximately 25% of the total outstanding shares of Alterola.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

6. Equity Method Investment in Alterola (continued)

 

Concurrently with the signing of the Secondary SPA, Bright Green and the Sellers entered into a voting agreement (the “Voting Agreement”) whereby the Sellers agree to vote in favor of the adoption of an agreement to effect Bright Green’s acquisition of Alterola or the Alterola’s merger into Bright Green or a subsidiary of Bright Green, as the case may be, pursuant to additional terms set forth in the Voting Agreement. The agreement will terminate upon the earlier of eight months from the date of the agreement or written notice by Bright Green.

 

Concurrently with the execution of the Voting Agreement, each Stockholder agrees to deliver to Bright Green an Irrevocable Proxy (“Proxy”). The Proxy only applies to the matter of voting upon the aspects regarding Bright Green’s purchase of the remaining 75% of Alterola’s common stock. It does not apply to the Stockholder’s voting on any other business matters pertaining to Alterola. As stated in the Proxy, Bright Green ensures the terms of the deal for the complete acquisition of Alterola are of no less value than as specified in the Press Release dated August 30, 2022, where the valuation of Alterola was determined to be $50 million. It is anticipated that the balance of the enterprise value will be paid as 20% of each shareholding in cash and the remaining 80% in Bright Green stock.

 

The Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Alterola common shares at cost, including transaction costs incurred to obtain the equity method investment of $339,115 in equity method investment in the condensed balance sheets.

 

Due to an inability to timely obtain the June 30, 2023’s financial information for Alterola, the following table provides summarized balance sheet information available for Alterola as of March 31, 2023 and December 31, 2022:

 

   March 31, 2023   December 31, 2022 
         
Current assets  $237,184   $192,011 
Non-current assets   12,139,779    12,018,147 
Current Liabilities   2,127,103    1,822,696 
Non-current liabilities   154,313    151,255 
Equity  $10,095,547   $10,236,207 

 

Due to an inability to timely obtain the June 30, 2023’s financial information for Alterola, the following table provides summarized income statement information available for Alterola for the three months ended March 31, 2023 and 2022:

 

   March 31, 2023   March 31, 2022 
   Three Months Ended 
   March 31, 2023   March 31, 2022 
         
Total revenues  $-   $- 
Net loss  $19,766   $3,257,819 

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

6. Equity Method Investment in Alterola (continued)

 

The Company’s ownership percentage of 25% of Alterola allows the Company to have significant influence over the operations and decision-making at Alterola. Accordingly, the investment is accounted for as an equity method investment. Since the June 30, 2023 financial results of Alterola will not be available until the third quarter of 2023, the Company will recognize its share of net loss from its investment in Alterola on a three-month lag and will adjust for any known significant changes from the lag period to the reporting date of the Company. The Company’s share of net loss from its investment in Alterola was $4,941 for the three months ended March 31, 2023. As at June 30, 2023, there were no significant changes to disclose.

 

On April 4, 2023, the Company announced its intention to acquire the remaining issued and outstanding common stock of Alterola. However, as of June 30, 2023, the Company is currently negotiating a new agreement with the Sellers.

 

Voting Agreement

 

The Voting Agreement was initially measured at fair value utilizing the Black-Scholes-option-pricing model based on the following assumptions: dividend rate of 0.0%, risk free rate of 4.0%, term of 0.5 years, volatility of 66.0%, the stock price of $26.4 million, inclusive of a Control Premium of 65% valued at $10.4 million, determined using the Recent Transaction Method as the transaction was determined to be arms-length, and a strike price of $61.3 million reflecting the option to purchase the remaining 75% of the outstanding shares of common stock for $46.0 million. The issuance date fair value of the Voting Agreement was determined to be $213,000 of the gross payment to the Sellers of $3,999,999.

 

As of December 31, 2022, the value of the option was impaired to $nil to reflect the likelihood that the option would be exercised according to the terms set forth. At June 30, 2023, the option has expired.

 

v3.23.2
Property, Plant, and Equipment
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant, and Equipment

7. Property, Plant, and Equipment

 

The Company owns an expansive 22-acre modern Dutch “Venlo style” glass greenhouse situated on 70 acres in Grants, New Mexico. It is being retrofitted for growing, processing and distribution of medicinal plants, including Marijuana, for medical researchers licensed by the Drug Enforcement Administration.

 

Property, plant, and equipment at June 30, 2023 and December 31, 2022, consisted of the following:

 

   June 30, 2023   December 31, 2022 
Furniture and fixtures  $88,690   $88,690 
Land   260,000    260,000 
Construction in progress   13,007,342    10,736,269 
Building and improvement   8,883,851    8,883,851 
Property, plant, and equipment gross   22,239,883    19,968,810 
Accumulated depreciation   (3,139,236)   (2,822,485)
Net property, plant, and equipment  $19,100,647   $17,146,325 

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

7. Property, Plant, and Equipment (continued)

 

The amount of interest costs capitalized and included in construction in progress totaled $269,473 and $106,117 as at June 30, 2023 and December 31, 2022, respectively (Note 10).

 

Real Estate Options

 

In 2020, the Company entered into a merger agreement with Grants Greenhouse Growers, Inc. and acquired the following two land options:

 

  - A Real Estate Option Agreement dated October 5, 2020, and expiring on December 31, 2021, for $1,500 monthly payments up until June 30, 2021, and $1,750 monthly payments from July 1, 2021 to December 31, 2021, with a one-year extension starting on January 1, 2022 for $2,000 monthly payments, with the option to purchase 330 acres for $5,000 per acre.
     
  - A Real Estate Option Agreement dated October 21, 2020, and expiring on December 31, 2021, for $1,000 monthly payments, with a one-year extension starting on January 1, 2022 for $1,500 monthly payments, with the option to purchase 175 acres for $5,000 per acre.

 

As of December 31, 2022, the Company notified the two land owners of the Company’s intention to exercise the two Real Estate Option Agreements. The Company is in the process of negotiating final terms of the two acquisitions. As of June 30, 2023, the acquisitions have not been completed.

 

v3.23.2
Intangible Assets
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

8. Intangible Assets

 

Intangible assets at June 30, 2023 and December 31, 2022, consisted of the following:

 

   June 30, 2023   December 31, 2022 
Licenses  $1,000   $1,000 
Accumulated amortization   -    - 
Net intangible assets  $1,000   $1,000 

 

v3.23.2
Commitments
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments

9. Commitments

 

In 2022, the Company entered a contract to purchase equipment for $2,219,285. The Company made a deposit totaling $1,109,643 as of December 31, 2022. The remaining balance of $1,109,642 is due upon delivery. The Company also entered into and paid in full a construction contract for $47,944 as of December 31, 2022. The construction was completed in March 2023, and the contract was fulfilled (Note 5).

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

v3.23.2
Related Party Line of Credit Note
6 Months Ended
Jun. 30, 2023
Related Party Line Of Credit Note  
Related Party Line of Credit Note

10. Related Party Line of Credit Note

 

On June 5, 2022, the Company and LDS Capital LLC (“Lender”), whose managing member is a member of the Board, entered into an unsecured line of credit in the form of a note (the “June Note”). The Note provides that the Company may borrow up to $5.0 million, including an initial loan of $3.0 million, through June 4, 2025 (the “June Note Maturity Date”) from Lender. Prior to the June Note Maturity Date, the Company may borrow up to an additional $2.0 million under the June Note, at Lender’s sole discretion, and subject to the Company’s request of such additional funds from Lender (each loan furnished under the June Note individually, a “Loan,” and collectively, the “Loans”). The Company has the right, but not the obligation, to prepay any Loan, in whole or in part, prior to the June Note Maturity Date. Interest on the unpaid principal amount of any Loan accrues through the earlier of the June Note Maturity Date or the date of prepayment on such Loan, at a rate of 2% per annum plus the Prime Rate (the rate of interest per annum announced from time to time by JPMorgan Chase Bank as its prime rate). If the principal and interest, if any, of any Loan is not paid in full on the Maturity Date, additional penalty interest will accrue on such Loan in the amount of 2% per annum. The Company amended the line of credit on November 14, 2022, to increase the capacity by $10 million. On January 31, 2023, LDS Capital LLC assigned the note to its sole member, Lynn Stockwell, who is a member of the Board and majority shareholder of the Company.

 

As of June 30, 2023, the Lender has funded the Company $5,783,250 (December 31, 2022  ̶  $5,191,057), with the Company paying back $2,491,066 (December 31, 2022  ̶  $1,611,067) of those funds. As of June 30, 2023, there was accrued interest of $269,473 (December 31, 2022  ̶  $106,117). The funds have been used for the construction in progress and interest expense of $269,473 (December 31, 2022  ̶  $106,117) has been capitalized (Note 7).

 

On February 1, 2023, through a cashless conversion, the related party line of credit note was used to pay in full the related party loan balance of $392,194.

 

On February 6, 2023, through a cashless conversion, the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment for 22,005 shares of the Company’s common stock valued at $39.99 per share pursuant to the Company’s EB-5 Program (Note 11).

 

On March 14, 2023, the Company drew an additional $200,000 on the related party line of credit note.

 

v3.23.2
Stockholders’ Equity
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders’ Equity

11. Stockholders’ Equity

 

The Company has authorized 500,000,000 shares of $0.0001 par value common stock and 10,000,000 shares of $0.0001 par value preferred stock. As of June 30, 2023, and December 31, 2022, there were 179,483,020 and 173,304,800, respectively, of common shares issued and outstanding. The Company has not issued any preferred shares to date.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

11. Stockholders’ Equity (continued)

 

During the six months ended June 30, 2023, the Company issued the following:

 

  - 200,000 warrants exercised in exchange for 200,000 shares of common stock issued for cash at $1.05 per share, to one accredited investor in February 2023;
     
  - 22,005 shares of common stock issued at $39.99 per share, to a member of the Board in February 2023, through a cashless conversion; the related party line of credit note was paid down $880,000 in exchange for an $880,000 investment, pursuant to the Company’s EB-5 Program (Note 10);
     
  - 22,005 shares of common stock issued at $39.99 per share, to one accredited investor in March 2023, pursuant to the Company’s EB-5 Program;
     
  - 875,000 shares of common stock for services rendered, at a fair value of $0.9416 per share, to the Company’s Executive Chairman, in March 2023 (Note 12);
     
  - 500,000 shares of common stock for services rendered, at a fair value of $1.13 per share, to the Company’s Chief Executive Officer, in May 2023 (Note 12);
     
  - 3,684,210 shares of common stock and warrants to purchase up to an aggregate of 3,684,210 shares of common stock, at a combined purchase price of $0.95 per share and accompanying warrant, in a private placement offering, in May 2023 (the “May 2023 Private Placement”); and
     
  - 875,000 shares of common stock for services rendered, at a fair value of $1.01 per share, to the Company’s Executive Chairman, in June 2023 (Note 12).

 

Private Placement Offerings

 

September 2022 Private Placement

 

On September 7, 2022, the Company entered into a Securities Purchase Agreement with investors for the sale by the Company of 9,523,810 shares of common stock and warrants to purchase up to an aggregate of 9,523,810 shares of common stock. The combined purchase price of one share and the accompanying warrant (“September 2022 Warrants”) was $1.05. Subject to certain ownership limitations, the September 2022 Warrants are exercisable immediately after issuance at an exercise price equal to $1.05 per share of Common Stock, subject to adjustments as provided under the terms of the September 2022 Warrants. The September 2022 Warrants have a term of five years from the date of issuance. The September 2022 Private Placement closed on September 12, 2022. The Company received gross proceeds of approximately $10 million before deducting transaction-related fees and expenses payable by the Company. As of June 30, 2023, 200,000 of the September 2022 Warrants have been redeemed for $210,000.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

11. Stockholders’ Equity (continued)

 

In connection with the September 2023 Private Placement, the Company entered into a Registration Rights Agreement with the investors. The Company’s registration statement on Form S-1 to register the securities issued in the September 2022 Private Placement went effective on September 21, 2022.

 

Transaction costs incurred related to the September 2022 Private Placement include the following: (i) placement agent fees of $800,000, (ii) legal expenses of $55,617, and (iii) escrow agent expenses of $7,650.

 

May 2023 Private Placement

 

On May 21, 2023, the Company entered into a Securities Purchase Agreement with an accredited investor and existing stockholder of the Company. The combined purchase price of one share and the accompanying warrant (“May 2023 Warrants”) was $0.95. Subject to certain ownership limitations, the May 2023 Warrants are exercisable immediately after issuance at an exercise price equal to $0.95 per share of Common Stock, subject to adjustments as provided under the terms of the May 2023 Warrants. The May 2023 Warrants have a term of five years from the date of issuance. The May 2023 Private Placement closed on May 24, 2023. The Company received gross proceeds of approximately $3.5 million before deducting transaction related fees and expenses payable by the Company.

 

In connection with the May 2023 Private Placement, the Company entered into a Registration Rights Agreement with the investor. The Company’s registration statement on Form S-3 to register the securities issued in the May 2023 Private Placement went effective on June 5, 2023.

 

Transaction costs incurred related to the May 2023 Private Placement include the following: (i) placement agent fees of $316,850, and (ii) legal expenses of $78,400.

 

Warrants

 

September 2022 Warrants

 

In the Company’s September 2022 Private Placement, Warrants to purchase up to 9,523,810 shares of Common Stock were issued (“September 2022 Warrants”). The September 2022 Warrants were initially exercisable at a price of $1.05 per share, subject to adjustment as set forth in the September 2022 Warrants, at any time after September 12, 2022 and will expire on September 13, 2027. In connection with the May 2023 Private Placement, the exercise price of the September 2022 Warrants issued in the September 2022 Private Placement was reduced to $0.95 per share.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

11. Stockholders’ Equity (continued)

 

The fair value of the September 2022 Warrants immediately prior to the modification was $7,399,000, and the fair value of the September 2022 Warrants immediately after the modification was $6,901,000, representing a decrease in fair value of $498,000. In accordance with ASU 2021-04, as the modification was a result of issuing equity and there was no increase in fair value, the Company accounted for the adjustment as a reduction of additional paid-in capital with a corresponding offset recorded to additional paid-in capital (i.e., net impact to additional paid-in capital of $nil).

 

May 2023 Warrants

 

In the Company’s May 2023 Private Placement, Warrants to purchase up to 3,684,210 shares of Common Stock were issued (“May 2023 Warrants”). The fair value of the May 2023 Warrants was determined utilizing a Black Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $0.78, exercise price of $0.95, term of five years, volatility of 165.0%, risk-free rate of 3.8%, and dividend rate of 0.0%). The grant date fair value of the May 2023 Warrants was estimated to be $1.6 million on May 24, 2024 and is reflected within additional paid-in capital as of June 30, 2023.

 

During the six months ended June 30, 2022, the Company issued the following:

 

  - 12,500 shares of common stock at a purchase price of $4.00 per share, for gross cash proceeds of $50,000, to one accredited investor in January 2022;
     
  - 500,000 shares of common stock for services rendered, at a fair value of $4.00 per share determined using the per share purchase price of the latest $4.00 private placement Round, to the Chief Financial Officer of the Company, in April 2022;
     
  - 1,574,490 shares of common stock for services rendered, at a fair value of $8.00 per share determined using the per share purchase price of the latest $8.00 private placement Round, to six consultants in April 2022;
     
  - 5,000 shares of common stock that were issued in January 2021 to a director of the Company, for services valued at $2.00 per share determined using the per share purchase price of the $2.00 Round, were canceled in April 2022;
     
  - 300,000 shares of common stock at a purchase price of $10.00 per share, for gross cash proceeds of $3,000,000, to two accredited investors in May 2022; and
     
  - 108,000 shares of common stock that were issued in June 2019 to a consultant of the Company, for services valued at $0.069 per share determined using an asset approach, were canceled in June 2022.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

v3.23.2
Related Party Transactions
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

12. Related Party Transactions

 

Other than the transactions disclosed elsewhere in the condensed financial statements, the following are the other significant related party transactions and balances:

 

Included in common stock issued for services during the six months ended June 30, 2023, were 1,750,000 shares of common stock issued to the Executive Chairman of the Company (Note 11).

 

Included in common stock issued for services during the six months ended June 30, 2023, were 500,000 shares of common stock issued to the Chief Executive Officer of the Company (Note 11).

 

At June 30, 2023, $800,000 was due to the Company’s former interim Chief Executive Officer, who is also the Company’s Executive Chairman. The amount, which includes $750,000 in accrued bonus, is included in accrued liabilities in the condensed balance sheet. The accrued bonus is expected to be paid in the first quarter of 2024 and is subject to Board of Director approvals.

 

At June 30, 2023, $75,000 was due to the Company’s Chief Executive Officer. The amount is included in accrued liabilities in the condensed balance sheet.

 

At June 30, 2023, $23,201 was due to a company majority owned by the Company’s Chief Executive Officer. The amount is included in accounts payable in the condensed balance sheets.

 

At June 30, 2023, $24,480 was due to a company wholly owned by the Company’s Chief Financial Officer, who also is a shareholder. The amount is included in accounts payable in the condensed balance sheet.

 

At June 30, 2023, the outstanding balance on the related party line of credit note of $3,561,657 was due to a Lender, who is a member of the Board (Note 10). The amount is included in the related party line of credit note in the condensed balance sheet.

 

v3.23.2
Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Contingencies

13. Contingencies

 

In the ordinary course of business, the Company is routinely defendants in, or parties to a number of pending and threatened legal actions including actions brought on behalf of various classes of claimants. In view of the inherent difficulty of predicting the outcome of such matters, the Company cannot state what the eventual outcome of such matters will be. Legal provisions are established when it becomes probable that the Company will incur an expense related to a legal action and the amount can be reliably estimated. Such provisions are recorded at the best estimate of the amount required to settle any obligation related to these legal actions as at the balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Management and internal and external experts are involved in estimating any amounts that may be required. The actual costs of resolving these claims may vary significantly from the amount of the legal provisions. The Company’s estimate involves significant judgement, given the varying stages of the proceedings, the fact that the Company’s liability, if any, has yet to be determined and the fact that the underlying matters will change from time to time. Other than as set forth below, the Company is not presently a party to any litigation. The Company is not able to make a reliable assessment of the potential losses as these matters are at an early stage, accordingly, no amounts have been accrued in the condensed financial statements.

 

Bright Green Corporation v. John Fikany, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company filed a complaint for declaratory judgment against a consultant of the Bright Green Group of Companies, an entity unrelated to the Company, to determine if defendant is entitled to 5,000,000 shares of the Company’s common stock, based on a failure to fulfill agreed upon conditions precedent to earning such shares from the Company. Defendant counterclaimed and filed a third-party claim against a director of the Company, and her spouse, for claims including wrongful termination and breach of contract. The Company denies defendants allegations and have set forth arguments refuting defendant’s counterclaims and third-party claims. The case is in the discovery phase. The Company is exploring potential dispositive motions against the counter and third-party claims.

 

Bright Green Corporation v. Jerry Capussi, State of New Mexico, County of Cibola, Thirteenth Judicial District. In this matter, the Company and defendant, a former consultant of Sunnyland Farms Inc., an entity unrelated to the Company, have each filed claims for declaratory judgment seeking to determine by court order whether defendant is entitled to (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of Bright Green Grown Innovation LLC. The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.

 

v3.23.2
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events

14. Subsequent Events

 

The Company’s management has evaluated the subsequent events up to August 16, 2023, the date the financial statements were issued, pursuant to the requirements of ASC 855, and has determined that the following constitute material subsequent events:

 

On July 31, 2023, the Company issued 137,838 shares to a consultant for professional services, pursuant to the terms of a consulting services agreement. 

v3.23.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Measurement

  A. Basis of Measurement

 

The condensed financial statements of the Company have been prepared on a historical cost basis except as indicated otherwise.

 

Property, Plant, and Equipment

  B. Property, Plant, and Equipment

 

Property, plant, and equipment is stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant, and equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property, plant, and equipment, except land, which is not depreciated, is provided using the declining balance method, or straight-line method, with estimated lives as follows:

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  B. Property, Plant, and Equipment (continued)

 

  Building and improvement - declining balance method 10 year life
  Furniture and fixtures - straight-line method 3 year life

 

Construction in progress is not depreciated until the asset is placed in service.

 

Long-lived Assets

  C. Long-lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC Topic 360 requires that long-lived assets be reviewed annually for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable; it further requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal.

 

Intangible Assets

  D. Intangible Assets

 

The Company’s intangible assets consist of certain licenses (Note 8) which will be amortized over the term of each license. The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets.

 

Fair Value of Financial Instruments

  E. Fair Value of Financial Instruments

 

In accordance with ASC 820 (Topic 820, Fair Value Measurements and Disclosures), the Company uses a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). The fair value hierarchy is divided into three levels based on the source of inputs as follows:

 

  Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  E. Fair Value of Financial Instruments (continued)

 

  Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly including inputs in markets that are not considered to be active; and
     
  Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying amounts of the Company’s cash, other assets, accounts payable, accrued liabilities, due to others, and due to related party approximated their fair values as of June 30, 2023 and December 31, 2022 due to their short-term nature.

 

Investments Under the Equity Method

   F. Investments Under the Equity Method

 

When the Company does not have a controlling financial interest in an entity but can exert significant influence over the entity’s operating and financial policies, the investment is accounted for either (i) under the equity method of accounting or (ii) at fair value by electing the fair value option available under U.S. generally accepted accounting principles (“GAAP”). Significant influence generally exists when the Company owns 20% to 50% of the entity’s common stock or in-substance common stock. In addition, the Company may recognize its share of an investee’s earnings based on an estimated amount for the investee’s earnings when the investee’s financial information is not sufficiently timely for the Company’s reporting period.

 

Under the equity method of accounting, investments are initially recorded at cost, including transaction costs incurred to acquire the investment, and thereafter adjusted for additional investments, distributions and the proportionate share of earnings or losses of the investee. The Company evaluated the equity method investment for impairment when events or changes in circumstances indicate that an other-than-temporary decline in value may have occurred.

 

Derivative Financial Instruments

 

The Company evaluates all its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the condensed statement of operations and comprehensive loss each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s condensed balance sheets.

Advertising Costs

  G. Advertising Costs

 

Advertising costs are charged to operations when incurred. Advertising costs totaled $20,333 and $35,857 for the six months ended June 30, 2023 and 2022, respectively.

 

Income Taxes

  H. Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized.

 

Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed its methodology for estimating the valuation allowance. A change in valuation allowance affects earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

 

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Basic and Diluted Earnings (Loss) per share

  I. Basic and Diluted Earnings (Loss) per share

 

Basic earnings (loss) per share is calculated using the weighted average number of common shares outstanding during the period. The dilutive effect on earnings per share is calculated, presuming the exercise of outstanding options, warrants and similar instruments. It assumes that the proceeds of such exercise would be used to repurchase common shares at the average market price during the period. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.

Segment Reporting

  J. Segment Reporting

 

ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for how public business enterprises report information about operating segments in the Company’s condensed financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. Significantly all of the assets of the Company are located in the United States of America and the Company is a start-up company as at June 30, 2023 and 2022 and has no revenue. The Company’s reportable segments and operating segments will include its growth, production and research of medicinal plants operations.

 

Use of Estimates

  K. Use of Estimates

 

The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to valuation allowance for deferred tax assets, valuation of warrants and stock-based compensation, going concern assessment, and assignment of the useful lives of property, plant, and equipment. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

Stock-based Compensation

  L. Stock-based Compensation

 

The Company accounts for stock-based payments in accordance with the provision of ASC 718, which requires that all stock-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the condensed statement of operations and comprehensive loss based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to stock-based awards is recognized over the requisite service period, which is generally the vesting period.

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  L. Stock-based Compensation (continued)

 

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive management, management, accounting, operations, corporate communication, financial and administrative consulting services.

 

Warrants

  M. Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB, ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each condensed balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed statements of operations and comprehensive loss.

 

Standards, Amendments, and Interpretations Adopted

  N. Standards, Amendments, and Interpretations Adopted

 

  1) Modification of Equity-Classified Written Call Options

 

In April 2021, The FASB issued ASU 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (here-after referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment

 

 

BRIGHT GREEN CORPORATION
Notes to the Condensed Financial Statements (Unaudited)
For the Three and Six Months Ended June 30, 2023 and 2022
(Expressed in United States Dollars)

 

3. Summary of Significant Accounting Policies (continued)

 

  N. Standards, Amendments, and Interpretations Adopted (continued)

 

  1) Modification of Equity-Classified Written Call Options (continued)

 

to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This update is effective for annual periods beginning after December 15, 2021, and interim periods within those periods, and early adoption is permitted. The Company adopted this accounting policy as of January 1, 2022.

 

  2) Leases

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of activities.

 

The new standard became effective for public business entities on January 1, 2019, with early adoption permitted. The new standard became effective for the Company on May 17, 2022, the date the Company became a public entity. The Company adopted this accounting policy as of May 17, 2022.

 

A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While the Company continues to evaluate certain aspects of the new standard, including those still being revised by the FASB, the new standard does not have a material effect on the Company’s financial statements. As of June 30, 2023, the Company has one month to month lease, whereas the new standard does not apply.

 

  3) Fair Value Measurement

 

In August 2018, the FASB issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which changes the fair value measurement disclosure requirements of ASC 820. This update was effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Effective October 4, 2022, the Company adopted FASB guidance on the recognition and measurement of financial instruments (Note 6).

v3.23.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Estimated Useful Life

 

  Building and improvement - declining balance method 10 year life
  Furniture and fixtures - straight-line method 3 year life
v3.23.2
Equity Method Investment in Alterola (Tables)
6 Months Ended
Jun. 30, 2023
Investments, All Other Investments [Abstract]  
Schedule of Financial Statement Information

 

   March 31, 2023   December 31, 2022 
         
Current assets  $237,184   $192,011 
Non-current assets   12,139,779    12,018,147 
Current Liabilities   2,127,103    1,822,696 
Non-current liabilities   154,313    151,255 
Equity  $10,095,547   $10,236,207 

 

Due to an inability to timely obtain the June 30, 2023’s financial information for Alterola, the following table provides summarized income statement information available for Alterola for the three months ended March 31, 2023 and 2022:

 

   March 31, 2023   March 31, 2022 
   Three Months Ended 
   March 31, 2023   March 31, 2022 
         
Total revenues  $-   $- 
Net loss  $19,766   $3,257,819 
v3.23.2
Property, Plant, and Equipment (Tables)
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property Plant and Equipment

Property, plant, and equipment at June 30, 2023 and December 31, 2022, consisted of the following:

 

   June 30, 2023   December 31, 2022 
Furniture and fixtures  $88,690   $88,690 
Land   260,000    260,000 
Construction in progress   13,007,342    10,736,269 
Building and improvement   8,883,851    8,883,851 
Property, plant, and equipment gross   22,239,883    19,968,810 
Accumulated depreciation   (3,139,236)   (2,822,485)
Net property, plant, and equipment  $19,100,647   $17,146,325 
v3.23.2
Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

Intangible assets at June 30, 2023 and December 31, 2022, consisted of the following:

 

   June 30, 2023   December 31, 2022 
Licenses  $1,000   $1,000 
Accumulated amortization   -    - 
Net intangible assets  $1,000   $1,000 
v3.23.2
Description of Business and Organization (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
May 21, 2023
Feb. 01, 2023
Sep. 07, 2022
May 31, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Apr. 30, 2022
Date of incorporation           Apr. 16, 2019      
Common Stock, Par or Stated Value Per Share           $ 0.0001   $ 0.0001  
Revenue           $ 0      
Common Stock [Member]                  
Aggregate shares of common stock issued         300,000   312,500    
Common Stock [Member] | Accredited Investor And Existing Stockholder [Member]                  
Sale of Stock, Number of Shares Issued in Transaction 3,684,210                
Common Stock, Par or Stated Value Per Share $ 0.0001                
Private Placement [Member]                  
Aggregate shares of common stock issued     9,523,810 3,684,210          
Shares issued price per share   $ 39.99              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     9,523,810 3,684,210          
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 1.05            
Private Placement [Member] | Accredited Investor And Existing Stockholder [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 3,684,210                
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.95                
Private Placement [Member] | Common Stock [Member]                  
Shares issued price per share                 $ 4.00
Private Placement [Member] | Maximum [Member]                  
Aggregate shares of common stock issued   12,609,152              
v3.23.2
Going Concern and Basis of Presentation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 06, 2023
Feb. 01, 2023
Feb. 28, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]                
Net loss       $ 2,992,171 $ 19,181,093 $ 5,605,436 $ 19,907,439  
Net cash used in operations           2,078,750 3,539,273  
Retained earnings accumulated deficit       39,681,257   39,681,257   $ 34,075,821
working capital       7,314,852   7,314,852   $ 7,030,929
Proceeds from issuance of common stock and warrants           3,104,750  
Warrants to purchase shares of common stock           880,000 3,050,000  
Proceeds from exercise of warrants           210,000  
Proceeds from related party line of credit           200,000 $ 2,000,000  
Long-term line of credit       $ 15,000,000   15,000,000    
Payment of related party loan   $ 392,194       392,194    
Related party line of credit paid $ 880,000   $ 880,000     $ 880,000    
Debt conversion, shares issued 22,005         22,005    
Conversion price $ 39.99     $ 39.99   $ 39.99    
Line of credit facility, remaining borrowing capacity       $ 11,400,000   $ 11,400,000    
v3.23.2
Summary of Estimated Useful Life (Details)
Jun. 30, 2023
Building [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 10 years
Furniture and Fixtures [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 3 years
v3.23.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Property, Plant and Equipment [Line Items]    
Advertising cost $ 20,333 $ 35,857
Income tax examination, description The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination.  
Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of entity common stock 20.00%  
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Percentage of entity common stock 50.00%  
v3.23.2
Concentration of Credit Risk (Details Narrative) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Risks and Uncertainties [Abstract]    
Cash FDIC insured amount $ 250,000  
Excess of FDIC insured limit $ 271,268 $ 187,821
v3.23.2
Schedule of Financial Statement Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Current assets $ 689,562       $ 689,562   $ 492,421  
Current Liabilities 8,004,414       8,004,414   7,523,350  
Non-current liabilities 3,561,657       3,561,657   3,686,107  
Equity 13,320,800 $ 11,759,471 $ 5,941,428 $ 7,544,053 13,320,800 $ 5,941,428 11,578,836 $ 8,220,399
Total revenues        
Net loss $ (2,992,171)   $ (19,181,093)   $ (5,605,436) $ (19,907,439)    
Alterola Biotech, Inc. [Member]                
Current assets   237,184         192,011  
Non-current assets   12,139,779         12,018,147  
Current Liabilities   2,127,103         1,822,696  
Non-current liabilities   154,313         151,255  
Equity   10,095,547         $ 10,236,207  
Total revenues            
Net loss   $ 19,766   $ 3,257,819        
v3.23.2
Equity Method Investment in Alterola (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Oct. 03, 2022
Mar. 31, 2023
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Common stock, shares authorized     500,000,000   500,000,000
Common stock, par value     $ 0.0001   $ 0.0001
Common stock, shares issued     179,483,020   173,304,800
Common stock, shares outstanding     179,483,020   173,304,800
Carrying value of equity method investments     $ 3,986,019   $ 3,990,960
Equity in net losses   $ 4,941 $ 4,941  
Voting Agreement [Member]          
Dividend rate 0.00%        
Rist free rate 4.00%        
Expected term 6 months        
Volatility rate 66.00%        
Stock price $ 26,400,000        
Control premium percentage 65.00%        
Control premium $ 10,400,000        
Stock price $ 61,300,000        
Outstaanding common shares percentage 75.00%        
Oustanding common shares value $ 46,000,000.0        
Fair value of agreement $ 213,000        
Alterola Biotech, Inc. [Member]          
Ownership percentage 25.00%   25.00%    
Equity method investment, description The Proxy only applies to the matter of voting upon the aspects regarding Bright Green’s purchase of the remaining 75% of Alterola’s common stock. It does not apply to the Stockholder’s voting on any other business matters pertaining to Alterola. As stated in the Proxy, Bright Green ensures the terms of the deal for the complete acquisition of Alterola are of no less value than as specified in the Press Release dated August 30, 2022, where the valuation of Alterola was determined to be $50 million. It is anticipated that the balance of the enterprise value will be paid as 20% of each shareholding in cash and the remaining 80% in Bright Green stock.        
Valuation amount $ 50,000,000        
Carrying value of equity method investments     $ 339,115    
Sellers [Member]          
Liability to the sellers     $ 1,650,000   $ 1,650,000
Sellers [Member] | Voting Agreement [Member]          
Number of shares sold, value $ 3,999,999        
Sellers [Member] | Alterola Biotech, Inc. [Member]          
Ownership percentage 67.00%        
Alterola Biotech, Inc. [Member]          
Common stock, shares authorized 2,000,000,000        
Common stock, par value $ 0.001        
Common stock, shares issued 807,047,948        
Common stock, shares outstanding 807,047,948        
Alterola Biotech, Inc. [Member] | Sellers [Member]          
Number of shares sold 201,761,982        
Number of shares sold, value $ 3,999,999        
v3.23.2
Schedule of Property Plant and Equipment (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Furniture and fixtures $ 88,690 $ 88,690
Land 260,000 260,000
Construction in progress 13,007,342 10,736,269
Building and improvement 8,883,851 8,883,851
Property, plant, and equipment gross 22,239,883 19,968,810
Accumulated depreciation (3,139,236) (2,822,485)
Net property, plant, and equipment $ 19,100,647 $ 17,146,325
v3.23.2
Property, Plant, and Equipment (Details Narrative)
6 Months Ended 9 Months Ended 12 Months Ended
Jan. 01, 2022
USD ($)
a
Oct. 21, 2020
Oct. 05, 2020
Dec. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Jun. 30, 2023
USD ($)
a
Dec. 31, 2022
USD ($)
Grant Greenhouse GrowersInc [Member] | Real Estate Option Agreement One [Member]                
Property, Plant and Equipment [Line Items]                
Area of land for purchase | a 330              
Expiration date     Dec. 31, 2021          
Monthly payments $ 2,000       $ 1,500      
Monthly payments for land       $ 1,750        
Expense made       5,000        
Grant Greenhouse GrowersInc [Member] | Real Estate Option Agreement Two [Member]                
Property, Plant and Equipment [Line Items]                
Area of land for purchase | a 175              
Expiration date   Dec. 31, 2021            
Monthly payments $ 1,500              
Monthly payments for land           $ 1,000    
Expense made       $ 5,000        
Venlo Style Green House [Member] | New Mexico [Member]                
Property, Plant and Equipment [Line Items]                
Area of land for purchase | a             22  
Construction in Progress [Member]                
Property, Plant and Equipment [Line Items]                
Interest costs capitalized             $ 269,473 $ 106,117
v3.23.2
Schedule of Intangible Assets (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Licenses $ 1,000 $ 1,000
Accumulated amortization
Net intangible assets $ 1,000 $ 1,000
v3.23.2
Commitments (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Jun. 30, 2023
Property, Plant and Equipment [Line Items]    
Purchase price $ 17,146,325 $ 19,100,647
Construction contract paid 47,944  
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Purchase price 2,219,285  
Deposits 1,109,643  
Remaining payment $ 1,109,642  
v3.23.2
Related Party Line of Credit Note (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Mar. 14, 2023
Feb. 06, 2023
Feb. 01, 2023
Feb. 28, 2023
Jun. 30, 2023
Dec. 31, 2022
Nov. 14, 2022
Jun. 05, 2022
Line of Credit Facility [Line Items]                
Payment of related party loan     $ 392,194   $ 392,194      
Related party line of credit paid   $ 880,000   $ 880,000 $ 880,000      
Investment transfer for repayment of loan   $ 880,000   $ 880,000        
Debt conversion, shares issued   22,005     22,005      
Conversion price   $ 39.99     $ 39.99      
Drew from related party line of credit $ 200,000              
Unsecured Line of Credit [Member] | LDS Capital LLC [Member]                
Line of Credit Facility [Line Items]                
Line of credit facility, maximum borrowing amount               $ 5,000,000.0
Increase in the line of credit capacity amount               3,000,000.0
Additional borrowing capacity               $ 2,000,000.0
Interest rate stated percentage               2.00%
Lender committed funds         $ 5,783,250 $ 5,191,057    
Repayments of other debt         2,491,066 1,611,067    
Accrued interest         269,473 106,117    
Interest costs capitalized         $ 269,473 $ 106,117    
Unsecured Line of Credit [Member] | LDS Capital LLC [Member] | Prime Rate [Member]                
Line of Credit Facility [Line Items]                
Interest rate stated percentage               2.00%
Amended Unsecured Line of Credit [Member]                
Line of Credit Facility [Line Items]                
Increase in the line of credit capacity amount             $ 10  
v3.23.2
Stockholders’ Equity (Details Narrative)
1 Months Ended 3 Months Ended 6 Months Ended
May 24, 2023
USD ($)
Feb. 06, 2023
USD ($)
Sep. 12, 2022
USD ($)
Sep. 07, 2022
$ / shares
shares
Jun. 30, 2023
$ / shares
shares
May 31, 2023
USD ($)
$ / shares
shares
Mar. 31, 2023
$ / shares
shares
Feb. 28, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
$ / shares
shares
May 31, 2022
USD ($)
$ / shares
shares
Apr. 30, 2022
$ / shares
shares
Jan. 31, 2022
USD ($)
$ / shares
shares
Jun. 30, 2019
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
shares
May 21, 2023
$ / shares
Feb. 01, 2023
$ / shares
Dec. 31, 2022
$ / shares
shares
Sep. 06, 2022
USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Common stock, shares authorized         500,000,000                 500,000,000   500,000,000       500,000,000  
Common stock, par value | $ / shares         $ 0.0001                 $ 0.0001   $ 0.0001       $ 0.0001  
Preferred stock, shares authorized         10,000,000                 10,000,000   10,000,000          
Preferred stock, par value | $ / shares         $ 0.0001                 $ 0.0001   $ 0.0001          
Common stock, shares issued         179,483,020                 179,483,020   179,483,020       173,304,800  
Common stock, shares outstanding         179,483,020                 179,483,020   179,483,020       173,304,800  
Related party line of credit paid | $   $ 880,000           $ 880,000               $ 880,000          
Investments exchanged for payment of credit | $   $ 880,000           $ 880,000                          
Warrants redeemed, shares                               200,000          
Warrants redeemed, value | $                               $ 210,000          
Placement agent fees | $ $ 316,850   $ 800,000                                    
Legal fees | $ 78,400   55,617                                    
Escrow deposit | $     7,650                                    
Warrants fair value | $     6,901,000                                   $ 7,399,000
Decrease in fair value of warrants | $     498,000                                    
Gross cash proceeds | $                           $ 1,448,750 $ 14,595,920 $ 2,272,650 $ 14,595,920        
Securities Purchase Agreement [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Warrant exercise price | $ / shares                                   $ 0.95      
Purchase price | $ / shares                                   $ 0.95      
Warrant term       5 years                           5 years      
Private Placement [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Warrant exercise price | $ / shares       $ 1.05                                  
Shares of common stock issued       9,523,810   3,684,210                              
Shares issued price per share | $ / shares                                     $ 39.99    
Warrants to purchase common stock       9,523,810   3,684,210                              
Purchase price | $ / shares       $ 1.05   $ 0.95                              
Gross proceeds from private placement | $ $ 3,500,000   $ 10,000,000                                    
Executive Chairman [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock for services                               1,750,000          
Chief Executive Officer [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock for services                               500,000          
One Accredited Investor [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Number of warrants exercised               200,000                          
Shares of common stock for services               200,000                          
Warrant exercise price | $ / shares               $ 1.05                          
Common Stock [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Common stock, shares authorized         500,000,000                 500,000,000   500,000,000          
Shares of common stock for services                           1,375,000 2,074,490 2,250,000 2,074,490        
Shares of common stock issued                             300,000   312,500        
Shares of warrants to purchase                           3,684,210   3,684,210          
Gross cash proceeds | $                           $ 139 $ 207 $ 227 $ 207        
Common Stock [Member] | Private Placement [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares issued price per share | $ / shares                     $ 4.00                    
Common Stock [Member] | Board Member [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock issued               22,005                          
Shares issued price per share | $ / shares               $ 39.99                          
Common Stock [Member] | One Accredited Investor [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock issued             22,005         12,500                  
Shares issued price per share | $ / shares             $ 39.99         $ 4.00                  
Gross cash proceeds | $                       $ 50,000                  
Common Stock [Member] | Executive Chairman [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock for services         875,000   875,000                            
Shares issued price per share | $ / shares         $ 1.01   $ 0.9416             $ 1.01   $ 1.01          
Common Stock [Member] | Chief Executive Officer [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock for services           500,000                              
Shares issued price per share | $ / shares           $ 1.13                              
Common Stock [Member] | Chief Financial Officer [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock for services                     500,000                    
Shares issued price per share | $ / shares                     $ 4.00                    
Common Stock [Member] | Six Consultants [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock for services                     1,574,490                    
Shares issued price per share | $ / shares                     $ 8.00                    
Common Stock [Member] | Six Consultants [Member] | Private Placement [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares issued price per share | $ / shares                     8.00                    
Common Stock [Member] | Directors [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares issued price per share | $ / shares                     $ 2.00 $ 2.00                  
Shares of common stock cancelled                     5,000 5,000                  
Common Stock [Member] | Two Accredited Investor [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock issued                   300,000                      
Shares issued price per share | $ / shares                   $ 10.00                      
Gross cash proceeds | $                   $ 3,000,000                      
Common Stock [Member] | Consultants [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Shares of common stock issued                         108,000                
Shares issued price per share | $ / shares                 $ 0.069       $ 0.069   $ 0.069   $ 0.069        
Shares of common stock cancelled                 108,000                        
Warrant [Member] | Private Placement [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Warrant exercise price | $ / shares           $ 0.95                              
Warrant term           5 years                              
Shares of warrants to purchase           3,684,210                              
Share price | $ / shares           $ 0.78                              
Warrants estimate value | $           $ 1,600,000                              
Warrant [Member] | Private Placement [Member] | Measurement Input, Option Volatility [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Dividend rate           165.00                              
Warrant [Member] | Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Dividend rate           3.08                              
Warrant [Member] | Private Placement [Member] | Measurement Input, Expected Dividend Rate [Member]                                          
Accumulated Other Comprehensive Income (Loss) [Line Items]                                          
Dividend rate           0.000                              
v3.23.2
Related Party Transactions (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]    
Long-term line of credit $ 3,561,657 $ 3,686,107
Executive Chairman [Member] | Accrued Liabilities [Member]    
Related Party Transaction [Line Items]    
Due to related party 800,000  
Accrued bonus 750,000  
Chief Executive Officer [Member] | Accrued Liabilities [Member]    
Related Party Transaction [Line Items]    
Due to related party 75,000  
Chief Financial Officer [Member] | Accounts Payable [Member]    
Related Party Transaction [Line Items]    
Due to related party 24,480  
Board Member [Member]    
Related Party Transaction [Line Items]    
Long-term line of credit $ 3,561,657  
Executive Chairman [Member]    
Related Party Transaction [Line Items]    
Stock issued for services 1,750,000  
Chief Executive Officer [Member]    
Related Party Transaction [Line Items]    
Stock issued for services 500,000  
Chief Executive Officer [Member] | Accounts Payable [Member]    
Related Party Transaction [Line Items]    
Due to related party $ 23,201  
v3.23.2
Contingencies (Details Narrative)
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Contingency, taken by defendant description (i) shares of common stock in the Company (amounting to no more than 108,000 shares) or (ii) fair market value of defendant’s equity ownership of Bright Green Grown Innovation LLC. The lawsuit is in early discovery stages, and the Company is preparing arguments for a summary judgment motion. There are no claims for specific monetary liability against either party.
v3.23.2
Subsequent Events (Details Narrative)
Jul. 31, 2023
shares
Subsequent Event [Member] | Consultant [Member]  
Subsequent Event [Line Items]  
Common stock issued for services (Note 11), shares 137,838

Bright Green (NASDAQ:BGXX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bright Green Charts.
Bright Green (NASDAQ:BGXX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bright Green Charts.